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List of abbreviations  
 
AB: antibiotic(s) 
ABC: ATP-binding cassette 
ABPA: allergic bronchopulmonary aspergillosis 
AFLP: amplified fragment length polymorphism analysis 
AHL: acyl homoserin lactone 
AP-PCR:arbitrarily primed polymerase chain reaction 
ASL: airway surface liquid 
ATP: adenosine triphosphate 
A. xylosoxidans: Achromobacter xylosoxidans 
BAL: broncho-alveolar lavage 
BALF: broncho-alveolar lavage fluid 
Bcc: Burkholderia cepacia complex 
BID: bis in die (= twice a day)  
BMI: body mass index 
B. cepacia: Burkholderia cepacia 
cAMP: cyclic adenosine monophosphate 
CBAVD: congenital bilateral absence of vas deferens 
CF: cystic fibrosis 
CFF: cystic fibrosis foundation  
CFTR: cystic fibrosis transmembrane conductance regulator 
CI: confidence interval  
CIE: counter immuno electrophoresis  
Cl-: chloride 
c.q.: casu quo 
DB: double blind 
DIOS: distal intestinal obstruction syndrome 
DNA: deoxyribonucleic acid 
ELISA: enzym-linked immunosorbent assay 
EnaC: epithelial sodium channel 
fAFLP: fluorescent amplified fragment length polymorphism analysis 
FEV1: forced expiratory volume in one second 
FVC: forced vital capacity 
GT: genotype 
HC: historic control 
HCO3-: bicarbonate 
HCW: health care worker 
H. influenzae: Haemophilus influenzae 
i.e.: id est  
IL: interleukin 
Inh: inhaled 
ip: inpatient 
IV: intravenous 
LBR: Laboratory for Bacteriology Research 
LES: Liverpool epidemic strain 
LF: lung function  
LPS: lipopolysaccharide 
LS: laryngeal suction 
m: month(s) 
MCC: mucociliary clearance 
MLST: multi locus sequence typing 
MRSA: methicillin resistant Staphylococcus aureus 
MSSA: methicillin senstitive Staphylococcus aureus 
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MU: million units  
NACFC: North American Cystic Fibrosis Conference  
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Pa: Pseudomonas aeruginosa 
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PC: placebo controlled 
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PCR: polymerase chain reaction 
PFGE: pulsed field gel electrophoresis 
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PPV: positive predictive value 
QS: quorum sensing  
RAPD: random amplification of polymorphic DNA analysis 
RCT: randomized controlled trial 
RNA: ribonucleic acid 
ROS: reactive oxygen species 
RSV: respiratory syncytial virus 
S. aureus: Staphylococcus aureus 
SD: standard deviation 
S. maltophilia: Stenotrophomonas maltophilia  
SNP: single nucleotide polymorphism 
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tDNA-PCR: tDNA intergenic length polymorphism analysis 
TG: treatment group 
TID: ter in die (= three times a day) 
TIP: tobramycin inhalation powder 
TLR: Toll-like receptor  
tRNA: transfer RNA 
TS: throat swab  
UK: United Kingdom 
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Chapter I: Cystic fibrosis 
Introduction 
Cystic fibrosis (CF) is the most common hereditary life shortening disease in the Caucasian 
population, affecting more than 100 000 people worldwide. The disease is caused by a defect in the 
CFTR protein, resulting in a defective transport of chloride across the cellular membrane. Hallmarks of 
the classic CF disease are progressive obstructive lung disease, pancreatic insufficiency and 
congenital absence of the vas deference in males. The prognosis for CF patients has improved 
substantially over the past 10-20 years, largely as a result of earlier diagnosis, more 
aggressive therapy, and provision of care in specialised centres. With a growing insight in the 
genetic defect  and pathophysiology of the disease, major advances are made in the 
treatment of CF and in the recognition of atypical CF disease.  
 
1. History  
Although the first descriptions of young children dying from cystic fibrosis date back from the 
mid 16th century; the first clear description of cystic fibrosis as a clinical entity was made in 
1938, by Dr Dorothy Andersen, pathologist at the New York Babies Hospital (1). She 
reported the clinical and pathological findings of 49 children, describing the characteristic 
neonatal meconium ileus, intestinal and respiratory complications and many other features of 
CF and particularly the characteristic pancreatic histology. Over the following years, CF was 
increasingly recognised as a hereditary multi-system disorder not only affecting the pancreas 
(displaying cystic fibrosis on pathological examination), but also other organs such as the 
respiratory tract and male reproductive system. Whereas in the early years CF babies did not 
survive early childhood, survival steadily increased thanks to the expanding knowledge on the 
disease, better therapies and better organised patient care, e.g. the advent of antibiotics and 
pancreatic enzyme replacement therapy in the fifties and the establishment of specialized CF centres 
for comprehensive care from the sixties on, with meticulous clinical and microbiological follow-up.  
 
2. Genetics  
The genetic defect causing CF was identified in 1989 by teams headed by Prof. Lap-Chee 
Tsui, Dr Collins and Prof. Riordan (2-4). They detected that CF results from a defect  in the 
cystic fibrosis transmembrane conductance regulator (CFTR) gene. This large gene is 
located on the long arm of chromosome 7 and spans 250 kb.  As shown in Figure 1, the gene 
is transcribed into a 6.5-kb messenger RNA that encodes a 1480 amino acid protein. The 
mature protein, properly folded, glycosylated and inserted in the cell membrane, is shown at 
the bottom of Figure 1. 
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Figure 1. The cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene and 
its encoded polypeptide.(5)  
 
 
 
 
The CFTR protein is a member of the ATP-binding cassette (ABC) family of transporters. It 
contains two nucleotide-binding domains that bind and hydrolyze ATP, two dual sets of 
membrane-spanning segments that form the channel, and a central regulatory (R) domain. 
The CFTR protein mainly functions as  a chloride (Cl-) channel that regulates the ion and 
water balance across epithelia. CFTR is principally expressed in the apical membrane of 
epithelia and submucosal glands where it provides a pathway for Cl- and bicarbonate (HCO3)  
movement and controls the rate of fluid transport through its role as an anion channel on the 
one hand and through the regulation of other ion channels and transporters on the other 
hand (6). Thus, CFTR plays a fundamental role in transepithelial fluid and electrolyte 
transport. In respiratory airway, intestinal and pancreatic epithelia CFTR powers the 
secretion of Cl- and HCO3-, while in sweat duct epithelia CFTR drives the reabsorption of salt.  
The mutations in the CF gene can disrupt CFTR function in different ways, ranging from 
complete loss of function to a reduced level of functional CFTR proteins. Mutations in the 
CFTR gene are currently classified into five groups according to their repercussion on CFTR 
protein synthesis and its chloride channel function (Figure 2).  
 
Class I mutations produce premature transcription termination signals resulting in unstable, 
truncated non-functional CFTR. These mutations include the stop codon mutations.  
Class II mutations, including F508del, result in an aberrantly folded CFTR protein that is 
degraded by the cell quality control system.  
Class III mutations lead to defective regulation of the CFTR protein.   
Class IV mutations give rise to a defective chloride conductance.  
Class V mutations result in reduced amounts of functional protein.  
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Figure 2. Class I-V mutations of CFTR (5) 
 
 
 
Since the identification of the gene, over 1500 CFTR mutations have been identified of which 
more than 1000 are known to cause CF while the remainder are involved in the milder CFTR 
related diseases or do not cause disease at all.  
Mutation classes I to III usually lead to a classic CF phenotype with pancreatic insufficiency, 
although the severity of lung disease is highly variable. Class IV and V mutations are often 
associated with a milder expression of the disease and with pancreatic sufficiency. In 
general, genotype-phenotype correlation is good for pancreatic insufficiency, but is weak for 
respiratory disease. Modifier genes, lifestyle, treatment, environment and age may all play an 
additional role in determining the phenotype of clinical disease (7).  
 
Cystic fibrosis is an autosomal recessively heritable disease. Two mutant CFTR genes are 
necessary to produce CF disease. A CF patient can either be homozygous (carrying an 
identical CFTR mutation on both CFTR alleles) or compound heterozygous (carrying two 
different CFTR mutations). The distribution of CFTR mutations differs between different 
ethnic populations. The most common mutation, F508del, reaches frequencies of 70% or 
more in northern European and North American populations, with lower frequencies in 
southern European populations. Although CFTR mutation frequency varies from population 
to population, worldwide no other single mutation accounts for more than approximately 5% 
of CFTR mutations (8).  
Table 1 represents the relative frequencies of different mutations in the Belgian population 
(9). 
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Table 1: CFTR mutation frequency  
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3. Epidemiology  
Cystic fibrosis affects more than 100 000 people worldwide. CF is more common in 
Caucasian populations. In Europe, prevalence varies from 1/1350 in Ireland to 1/25000 in 
Finland (10). The prevalence of CF in Belgium is 1/3700. Carrier frequency varies from 1/20 
to 1/80. The prevalence of CF in North-America is approximately the same as in Europe 
(1/3500). CF is less common in Latin America, the Middle East and South Africa with 
prevalence rates ranging from 1/5000 to 1/20000 (6). Cystic fibrosis is uncommon in Africa 
and Asia, with a reported frequency of 1/350 000 in Japan (11). Due to better medical 
surveillance and better treatments CF no longer is a disease of childhood. Whereas in the 
early years of CF, babies did not survive early childhood, survival has increased considerably 
over the last decades (table 3). In Belgium, as in other countries, close to 50% of the CF 
patients are 18 years or older, reflecting the better survival, but probably also showing the 
result of increased diagnosis of atypical CF disease. At present, the median predicted 
survival of an individual with CF in the USA is 37.4 years (figure 3) (12). Data from the 
German Cystic Fibrosis registry in 2005 showed similar survival figures with a median 
cumulative survival of 37.4 years (13).  
 
Figure 3 : Median predicted survival age 1986-2008 (12) 
 
 
 
In 2008, 25651 patients (age range 0-82years) were followed in the US; of which 46,3% 
older than 18 years. Seventy percent of the CF patients are diagnosed before the age of 1 
year, and 90% before their 8th birthday. Median age for diagnosis was 6 months; 42.8% of 
the newly diagnosed patients were detected through newborn screening (12).  
In Belgium 1087 CF patients were followed in the CF Reference Centres in 2008 (Table 2) 
(9). The median age was 18.1 years (age range 0.1-67.4 years). The percentage of adults 
(>18 years) has risen steadily and represented 50.2% of the total number of patients. The 
median age at diagnosis was 6.9 months and at the age of 18 years 93% of the patients are 
diagnosed. In 2008, 20% percent of the newly diagnosed CF patients were detected by the 
neonatal screening test, which is locally organised in some Belgian provinces.  
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Table 2: General Data Belgisch Mucoviscidose Register Annual Data Report 2008 (14).  
 
Number of CF patients: 1087 
Number of CF patients with data records: 1072 
Number of CF patients without observation: 15 
New CF diagnoses: 25 
Median patient age in years (range)*: 18.1 (0.1 - 67.4) 
Median patient age males (range)*: 17.5 (0.1 - 57.5) 
Median patient age females (range)*: 18.7 (0.2 - 67.4) 
Males : 51.7% 
Adults ≥ 18 years : 50.2% 
Median age at diagnosis: 6.9m 
Age range at diagnosis: 0.0 - 65.0y 
Median age at diagnosis males : 7.0m 
Age range at diagnosis males : 0.0 - 55.7y 
Median age at diagnosis females: 6.8m 
Age range at diagnosis females: 0.0 - 65.0y 
Median age at diagnosis new cases in years (range): 1.3 (0.0 - 17.1) 
Number of transplants performed in 2008: 14 
Number of deaths reported occurring in 2008: 5 
Median age at death in years (range): 25.5 (17.5 - 45.8) 
Overall mean Wang-Hankinson FEV1 % predicted (SD): 77.0 (25.0) 
Mean FEV1 % predicted males (SD): 78.9 ( 25.4) 
Mean FEV1 % predicted females (SD): 74.8 (24.3) 
*Age of the patient at the last consultation 
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4. Clinical manifestations  
The CFTR protein is expressed in many of the epithelial surfaces throughout the body, 
including sinuses, lungs, pancreas, liver and the reproductive system. Consequently, disease 
manifestations can be encountered in the different anatomical sites of the body. Signs and 
symptoms consistent with CF are listed in Table 3.   
 
Table 3 : Phenotypic features consistent with a diagnosis of CF (15) 
 
1) Chronic sinopulmonary disease manifested by  
• Persistent colonisation/infection with typical CF pathogens including Staphylococcus 
aureus, nontypeable Haemophilius influenzae, mucoid and nonmucoid Pseudomonas 
aeruginosa and Burkholderia cepacia.  
• Chronic cough and sputum production.  
• Persistent chest radiograph abnormalities (e.g. bronchiectasis, atelectasis, 
infiltrates, hyperinflation)  
• Airway obstruction manifested by wheezing and air trapping.  
• Nasal polyps; radiographic or computed tomographic abnormalities of the paranasal 
sinuses. 
• Digital clubbing.  
2) Gastrointestinal and nutritional abnormalities including  
• Intestinal: meconium ileus, distal intestinal obstruction syndrome, rectal prolapse.  
• Pancreatic: pancreatic insufficiency, recurrent pancreatitis.   
• Hepatic: chronic hepatic disease manifested by clinical or histologic evidence of 
focal biliary or multilobular cirrhosis.  
• Nutritional: failure to thrive, hypoproteinemia and edema, complications secondary 
to fat-soluble vitamin deficiency.   
3) Salt loss syndromes: acute salt depletion, chronic metabolic alkalosis.   
4) Male urogenital abnormalities resulting in obstructive azoospermia (CBAVD).  
 
 
 Phenotypic features consistent with a diagnosis of CF
 
 
 
• Pulmonary  
The most striking manifestations of the disease occur in the lungs. Symptoms of recurrent or 
chronic productive cough can start early on in life. Chronic pulmonary infections in CF 
patients progress to bronchiectasis, hypoxemia and hypercarbia. Respiratory insufficiency is 
responsible for at least 80% of CF-related deaths (12). CF patients often have digital 
clubbing as result of chronic inflammation. CF causes chronic pulmonary infections with only 
a few pathogens, not all of them are pathogenic for non-CF people. The most important 
infecting bacteria are: P.  aeruginosa, S. aureus, H. influenzae, Stenotrophomonas 
maltophilia, Achromobacter xylosoxidans and B. cepacia complex (16). The organism most 
frequently discovered in CF sputum is P.  aeruginosa. As pulmonary infections with P.  
aeruginosa in CF patients are the main topic of this thesis, this subject will be elaborated in 
Chapters II and III.  
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• Gastro-intestinal  
- Pancreas  
Abnormal CFTR function in the pancreatic ducts causes a decreased volume of pancreatic 
secretions with reduced bicarbonate concentration (17). Autoactivation of retained digestive 
proenzymes leads to destruction and fibrosis of pancreatic tissue. Exocrine pancreatic 
insufficiency, leading to fat malabsorption and consequently steatorrhoea, fat-soluble-vitamin 
deficiency, and malnutrition is present in 85 to 90% of the CF patients. It can be present at 
birth or evolve over the first year of life. Typical signs of pancreatic insuffiency are greasy 
stools, flatulence, abdominal bloating, and poor weight gain. Exocrine pancreatic 
insufficiency can be overcome by the administration of pancreatic enzymes. Pancreatitis due 
to intermittent duct obstruction can occur in pancreatic-sufficient patients and may be the 
lead to diagnosis in older patients. 
- Liver  
Cholestasis secondary to common bile duct obstruction with inspissated bile may be the 
earliest manifestation of CF (18). 
Patients with CF are at risk for focal biliary cirrhosis caused by obstruction of intrahepatic bile 
ducts, but clinically apparent cirrhosis occurs  only in about 5% of patients (19). Liver 
cirrhosis may result in portal hypertension, with bleeding oesophageal varices and 
splenomegaly with signs of hypersplenism. In general, the clinical picture is one of very 
slowly progressive liver disease (20).  
- Intestines  
Meconium ileus is present in about 15% of newborns with cystic fibrosis. The bowel 
obstruction is secondary to the accumulation of inspissated intraluminal meconium. Distal 
intestinal obstructive syndrome (DIOS) is the equivalent of meconium ileus of the neonate.  
Patients present with signs of abdominal obstruction or more commonly subacutely with 
cramping abdominal pain.  
 
Until recently many children with CF were of below normal weight and height and had 
delayed puberty. Those who reached adulthood were of relatively short stature. Factors 
which contribute to the poor nutritional status of many CF patients include an inadequate 
energy intake, the often severe and rarely completely controlled intestinal malabsorption and  
the increased energy demands resulting from chest infection. With present-day treatment, 
the majority of people with CF should have a normal rate of growth, nutritional status and 
body composition.  
 
• Upper airways 
Nasal polyps are found frequently in CF patients, the incidence raising with increasing age 
from 10% to 32%. Nasal obstruction is the most common symptom and the reason for 
removal of polyps but recurrence rate is high. The occurrence of nasal polyps can be a lead 
to diagnosis in older, more mildly affected CF patients.  
The sinuses are infected in more than 90% of patients with CF but bacterial flora does not 
always correlate with the lower airways. It is however important to consider that sinuses may 
act as a long term reservoir for pulmonary infection (21).  
 
• Endocrine system 
The endocrine pancreatic function is initially spared from pancreatic fibrosis in CF patients. 
CF related diabetes mellitus (CFRDM) affects over 30% of adults with CF (12). These 
patients gradually develop carbohydrate intolerance and insulin insufficiency. Current 
guidelines advice to perform an annual oral glucose tolerance test from the age of 10 years 
on to detect CFRDM in an early stage (22).  
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• Reproductive system 
- Male fertility  
Ninety-five percent of the males with CF are infertile, but sexual function is not affected. 
Infertility results from structural abnormalities of the reproductive tract. The most common 
structural defect in CF males is the congenital absence of the vas deferens, giving rise to an 
obstructive azoospermia (23). This phenomenon can also be seen in men with only one 
CFTR mutation and no other manifestations of CF.  
 
- Female fertility  
Women with CF have anatomically normal reproductive tracts, but abnormalities of cervical 
mucus have been described. The formation of thick, tenacious cervical mucus may reduce 
sperm penetration. Women with severe respiratory disease and poor nutritional status are 
likely to have amenorrhoea and anovulatory cycles. Although there is some controversy 
about the effects of pregnancy in cystic fibrosis, the consensus is that a woman who has 
adequate nutritional and pulmonary reserve can successfully complete the term of 
pregnancy. 
 
• Osteoporosis  
 
Osteoporosis is more and more being recognised as a complication of CF. Osteoporosis in 
CF is of multifactorial origin and can be secondary to vitamin D deficiency, low body weight, 
decreased physical activity, delayed puberty, chronic inflammation and corticosteroid use.  
The 2008 CFF Patient Registry reports that about 20% of the CF patients from the age of 25 
years on suffer from osteoporosis (12).  
 
• Variability of clinical spectrum and disease severity in CF patients 
Manifestations of cystic fibrosis can appear throughout life, with great variability within 
individuals. Median age at diagnosis according to the 2008 Annual Report of the Belgian 
Cystic Fibrosis Registry data is 6.9 months (14). The clinical symptoms leading to diagnosis 
are outlisted in table 4 (9).   
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Table 4: Clinical symptoms leading to diagnosis of CF (Belgisch Mucoviscidose Register 
Annual Data Report 2008) (14) 
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5. Diagnosis of CF  
The diagnosis of CF should be considered and diagnostic work-up should be done in any 
patient of any age presenting with phenotypic features consistent with CF (see table 4) or a 
family history of CF.  Diagnosis of CF is mainly made on clinical grounds and should be 
confirmed by a positive sweat test. The sweat test, developed by Gibson and Cook in 1959 
and using pilocarpine iontophoresis, remains the most gold standard in making the diagnosis 
of CF, provided it is done according to strict guidelines (24). Sweat test is positive if the 
concentration of chloride in sweat is greater than 60 mmol/L.  A helpful method in assessing 
individuals who might have CF, but who do not meet classic diagnostic criteria (positive 
sweat test + 2 CFTR mutations), is measurement of nasal transepithelial potential difference 
(NPD) to assess chloride channel function (7, 25).  
The number of children diagnosed through newborn screening for CF is growing. Newborn 
screening is done by the measurement of immunoreactive trypsinogen (IRT) in blood spots 
taken from newborn infants. A very high IRT concentration suggests pancreatic injury 
consistent with (but not specific for) cystic fibrosis. A positive screening result only indicates 
that a child is at increased risk for cystic  fibrosis; a sweat test must still be done to confirm 
the diagnosis. Several studies have shown that newborn screening for cystic fibrosis leads to 
improved nutritional outcomes (26, 27). There is some evidence of improved survival in 
newborns diagnosed before the age of 1 month compared to infants diagnosed later (28) 
National programmes for neonatal screening exist in  the USA, the UK, Russia, France , 
Austria and are organized locally in many other European countries (29). About 3 000 000 
infants per year are screened (29).  
 
 
6. Classic or typical CF; non-classic or atypical CF;  CFTR related diseases.   
With expanding knowledge on CFTR function and mutation analysis, milder CF disease and 
diseases associated with CFTR mutation are increasingly recognised (7).  
Distinction should be made between these three entities: 
- classic or typical CF:  
Patients are diagnosed with classic or typical CF if they have one or more phenotypic 
characteristics consistent with CF and a sweat chloride concentration of >60 mmol/l. The 
vast majority of CF patients falls into this category. Usually one established mutation causing 
CF can be identified on each CFTR gene. Patients with classic CF can have exocrine 
pancreatic insufficiency or pancreatic sufficiency. The disease can have a severe course with 
rapid progression of symptoms or a milder course with very little deterioration over time. 
- non-classic or atypical CF:  
Patients with non-classic or atypical CF have a CF phenotype in at least one organ system 
and a normal (<30 mmol/l) or borderline (30–60 mmol/l) sweat chloride level. In these 
patients confirmation of the diagnosis of CF requires detection of one disease causing 
mutation on each CFTR gene or direct quantification of CFTR dysfunction by nasal potential 
difference measurement. Non-classic CF includes patients with multiorgan or single organ 
involvement. Most of these patients have exocrine pancreatic sufficiency and milder lung 
disease. 
CFTR related disease:  
Some patients with single organ involvement resulting from CFTR dysfunction may be more 
appropriately given an alternative diagnostic label as recommended in the World Health 
Organization (WHO) diagnostic list (Table 5) (30).  The number of these people recognised 
as having milder problems possibly associated with CFTR dysfunction is growing. These 
problems include male infertility, recurrent pancreatitis, chronic sinusitis, and primary 
sclerosing cholangitis (31). Congenital bilateral absence of the vas deferens (CBAVD) in 
infertile males has been associated with a high incidence of CF mutations (32). Some 
infertile males have two mutations, the most common being F508del/R117H- (33). Eighty to 
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ninety percent of men with CBAVD carry at least one and 50-60% have two CFTR mutations, 
usually one is CF-causing and the other is a CFTR-related disorder associated mutation (7, 
34).  
Sharer and Cohn evaluated the possible role CFTR in chronic pancreatitis and detected that 
a significant proportion of people with pancreatitis were carriers of a CF mutation; the 
frequency of a single mutation was 11 times greater than the expected frequency in a control 
population (35, 36). 
 
 
Table 5: WHO diagnostic list for single organ disease phenotypes associated with CFTR 
mutations  
 
Isolated obstructive azoospermia 
Chronic pancreatitis 
Allergic bronchopulmonary aspergillosis 
Disseminated bronchiectasis 
Diffuse panbronchiolitis 
Sclerosing cholangitis 
Neonatal hypertrypsinogenaemia 
 
 
7. Respiratory pathogens   
i. Bacteria  
 
The lungs of CF patients are colonized by bacterial pathogens, these are frequently acquired 
in an age-dependent sequence. The bacterial species most commonly associated with 
respiratory tract infection in CF include common human pathogens such as Staphylococcus 
aureus and Haemophilus influenzae as well as several opportunistic pathogens, of which 
Pseudomonas  aeruginosa is the most important one. Other opportunists include 
Stenotrophomonas maltophilia and Achromobacter xylosoxidans and species that are only 
occasionally associated with human infections apart from CF, such as the Burkholderia 
cepacia complex.  
We can divide the infecting organisms in ‘early infectors’ and ‘late infectors’. 
Early infectors are S. aureus, H. influenzae and P. aeruginosa, while late infectors are  B. 
cepacia complex, S. maltophilia and  A. xylosoxidans. The other late infectors, the 
nontuberculous mycobacteria and fungi are discussed later on in this chapter.  
The pattern of age-specific prevalence as well as overall prevalence of these pathogens in 
the CF population in the United States is demonstrated in Figure 4 from the Cystic Fibrosis 
Foundation Patient Registry 2008 data (12). The microbiology data of the Belgian CF 
Registry 2008 (9, 14) are represented in Figure 5. It must be noted that CF respiratory 
infection often is polymicrobial (37).  
Other emerging  bacteria which are not discussed below are Ralstonia and Cupriavidus 
species, Pandoraea species, Inquilinus limosus and anaerobic species (16).  
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Figure 4: CF microbiology (USA CFF Patient Registry 2008) (12) 
 
 
 
 
Figure 5: CF microbiology (Belgisch Mucoviscidose Register Annual Data Report 2008) (14) 
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Staphylococcus aureus 
 
S. aureus is often the first and is among the most common bacterial pathogens recovered 
from the respiratory tract of persons with CF (38-40). In the pre-antibiotic area, S. aureus 
caused substantial morbidity and mortality in infants with CF (40). Continuous, anti-
staphylococcal antibiotic prophylaxis is effective in reducing the incidence of infection with 
methicillin-sensitive S. aureus (MSSA) but an improvement in clinical outcome has not been 
shown (41). Moreover, there is some concern that antibiotic prophylaxis, especially with oral 
cephalosporins, might  increase the incidence of P. aeruginosa (42, 43). Therefore, anti-
staphylococcal antibiotic prophylaxis is not widely used. In recent years, the prevalence of 
methicillin resistant S. aureus (MRSA) in the CF population increased. Although initially 
questioned, there is now a growing evidence that MRSA might accelerate clinical 
deterioration and  increase morbidity in CF patients (44, 45). Numerous protocols for 
eradication of MRSA in CF patients have been reported in literature, with an overall 
eradication rate of 80% (46-48).   
 
Haemophilus influenzae 
 
H. influenzae is also isolated from the respiratory tract early in the course of CF (39). The H. 
influenzae strains infecting CF patients are not capsulated and thus not prevented by 
childhood immunization against H. influenzae type b. The role of H. influenzae in progressive 
airway infection and inflammation in CF patients has not been clearly demonstrated. There 
are no trials to demonstrate benefit from eradication of H. influenzae from respiratory cultures 
in CF. 
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Pseudomonas aeruginosa  
 
P.  aeruginosa has been regarded in the previous decades as a ‘late infector’. However, 
several recent studies have shown that infection occurs much earlier than previously believed 
(49, 50). Initially, P. aeruginosa grows as a non-mucoid strain that can be cleared by the host 
or eradicated with aggressive antibiotic treatment. Over time, P. aeruginosa colonies 
synthesize an alginate coat and form biofilms. These biofilms, once established, are difficult if 
not impossible to clear with standard antibiotic treatment. The epidemiology, clinical impact 
and treatment of P. aeruginosa in CF patients is reviewed extensively in Chapter II.  
 
Burkholderia cepacia complex 
 
B. cepacia is a late infector in cystic fibrosis. The “B. cepacia complex” (Bcc) is not a single 
species but rather a group of closely related species, "genomovars”. The vast majority of CF 
airway infections with B. cepacia complex are caused by genomovars II (Burkholderia 
multivorans), III (Burkholderia cenocepacia) and V (Burkholderia vietnamiensis) (51, 52). 
Genomovar III is higly virulent  and transmissible and is feared because of its association 
with the B. cepacia syndrome, which can lead to death due to bacteremia and necrotizing 
pneumonia. Most patients infected with B. cepacia complex however have a more chronic 
course, associated  with lung function decline  and increased mortality (53). A combination of 
antibiotics is used to treat B. cepacia complex, as most organisms  within the B. cepacia 
complex exhibit high levels of antibiotic resistance (54, 55).  
 
Stenotrophomonas maltophilia  
 
Isolation of S. maltophilia from sputa of patients with CF has increased markedly since the 
early 1980s (12, 56, 57). The precise reasons for this rise are unclear. The origin of S. 
maltophilia is unknown for most patients. Both the natural environment and other patients 
might be a possible source, although modes of transmission have not been identified exactly 
(58-60). Both transient and persistent infections can occur (16). The pathogenic role of S. 
maltophilia  in the CF lung disease remains an area of uncertainty and debate (57, 60-65). S. 
maltophilia is resistant to most anti-pseudomonal antibiotics (66). In most studies only co-
trimoxazole appears to have consistent activity, with more than 90% of the isolates being 
susceptible in vitro. UK guidelines (67) advice that only those patients chronically infected 
with S. maltophilia  who exhibit evidence of clinical deterioration should receive antibiotic 
treatment targeted at this organism.  
 
Achromobacter  xylosoxidans  
 
The prevalence of A. xylosoxidans in CF patients is rising (12, 68).  A. xylosoxidans, as S. 
maltophilia, is encountered in CF patients with advanced lung disease. The source and 
routes of acquisition are unknown for most patients, although CF patients can share 
genetically identical strains (69, 70). Although infection with A. xylosoxidans is frequently 
transient, chronic infection can occur and is most often due to the persistence of the same 
strain (70-72).  
Uncertainty still remains regarding its clinical significance in CF patients, although there is 
growing evidence that it causes an increase in morbidity. While Tan et al. (73) found no 
evidence of attributable clinical deterioration two years post-acquisition of A. xylosoxidans, 
De Baets et al. (74) observed that  patients with chronic A. xylosoxidans infection had lower 
chest X-ray scores and pulmonary function parameters and required more courses of 
antibiotics than age- and P. aeruginosa colonization status matched CF patients. However, 
no accelerated decline in respiratory function was observed during the study period (1.5 +/- 
0.9 years) . Hansen et al. (72) notified that A. xylosoxidans was associated with declining 
respiratory function if there was a rapid rise in specific precipitating antibodies in serum. A. 
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xylosoxidans is often multi-resistant and clinical data regarding optimal therapy are lacking. 
In vitro data suggest that the most active agents may be minocycline, meropenem or 
imipenem, piperacillin-tazobactam and chloramphenicol (75). 
Possibly, the prevalence of this species may be higher, because A. xylosoxidans may be 
misidentified as an ‘atypical P. aeruginosa isolate’ in many laboratories (69, 74).  
 
ii. Nontuberculous mycobacteria:  
 
Nontuberculous mycobacteria (NTM) are increasingly reported from the respiratory 
secretions of patients with CF. The species most commonly isolated are Mycobacterium 
avium complex and M. abscessus. Studies conducted in the USA and France have 
demonstrated a prevalence ranging from 7% to 24% (76, 77). Different NTM types are found 
in different age groups and in different geographical regions (76, 78). The origin of NTM in 
CF is likely to be the environment, and there is little evidence for interpatient transmission of 
these species (76, 79). Jonsson and colleagues (80) observed that a shared strain of NTM 
was only found in one pair of siblings out of 14 CF patients with NTM infection. 
The significance of the isolation of NTM from respiratory secretions remains unclear. NTM 
can represent transient contamination or colonization of the airway of CF patients but can 
also cause granulomatous disease (81). All CF patients should be screened annually for 
NTM. Patients with persistently positive sputum smears or cultures should be monitored 
closely for development of granulomatous disease (81). The American Thoracic Society 
criteria for diagnosis of disease have been revised in 2007 (82).  Although not specifically 
designed for CF, they are helpful in guiding investigation. 
 
iii. Fungi 
 
Aspergillus fumigatus is the most common filamentous fungus involved in CF lung disease. 
The prevalence of A. fumigatus  is low in young children with CF but increases steadily with 
age (83). Reported prevalence rates vary from 6% to nearly 60% (16). The origin of A. 
fumigatus is probably the environment, as it is an ubiquitous fungus, found in air, water, soil 
and rotting vegetation. The most frequently encountered fungal problem in CF is allergic 
bronchopulmonary aspergillosis (ABPA). Other clinical presentations include invasive 
pulmonary aspergillosis, aspergillus bronchitis, and aspergilloma. 
ABPA is an immune-mediated bronchial disease causing bronchiectasis as a result of 
exposure to A. fumigatus. The cause of ABPA is not an invasive fungal infection but a type I 
and III sensitization against allergens from A. fumigatus in the environment, leading to a 
clinical syndrome with wheezing, pulmonary infiltrates and, if untreated, bronchiectasis and 
pulmonary fibrosis (84). Prevalence in CF is reported to be between 2 and 8% (85-87).  
Treatment of ABPA consists of systemic steroids in conjunction with an azole antifungal 
agent.   
Invasive pulmonary aspergillosis is a rare but serious form of aspergillosis, mainly seen in 
immunosuppressed individuals. For persons with CF it is most likely to occur post 
transplantation.  
Other fungal species, including Exophiala dermatitidis and Scedosporium species, are 
increasingly reported from CF respiratory samples (83). Scedosporium apiospermum has 
been associated with a symptom complex similar to that of ABPA (88). It is also capable of 
causing invasive disease with high mortality post lung-transplant (89, 90). The significance of 
Exophiala dermatitidis in CF remains uncertain (90).  
. 
 
iv. Viruses  
 
Viruses have a well-recognized role in exacerbations of respiratory disease in CF patients 
(91-99). The frequency of respiratory viral infections and distribution of viruses involved do 
not differ between CF patients and non-CF controls (93, 96, 100).  However, viral respiratory 
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infections in CF patients are often more severe, of a longer duration (93, 96, 98) and can 
result in a decreased pulmonary function (91, 93, 98). Viral respiratory infections may 
predispose CF patients to bacterial infection, including infection with P. aeruginosa (92, 93, 
96, 97, 101-104). Van Ewijck et al. (104) demonstrated that more than a third of non-CF 
individuals carry P. aeruginosa  transitorily in the airways at times of acute viral respiratory 
infections during the winter months, but that they clear the organism spontaneously at 
recovery. In contrast, 30% of the CF people who become P. aeruginosa positive during colds 
often fail to clear the infection spontaneously when the viral infection settles. The same study 
group proved that RSV infection facilitates acute colonization with P. aeruginosa in mice 
(103). 
 
8. Treatment   
 
Appropriate and early initiated therapy is of paramount importance in CF patients.  
Treatment in CF is extensive and is started as soon as CF is diagnosed. Treatment includes 
pancreatic enzyme replacement therapy, high-fat and high-energy diet, chest physiotherapy 
and inhalation therapy. Treatment is burdensome: in a survey of adult patients with CF, 
subjects reported spending an average of 108 minutes (SD +/- 58 min) on daily CF 
treatments (105). In case of end stage pulmonary disease, lung transplantation can be 
performed. In patients with advanced lung disease, oxygen therapy and non-invasive 
ventilation is introduced awaiting lung transplantation. Future therapies and areas of 
intensive research include gene therapy, therapies to restore the airway surface liquid (ASL) 
and therapies to restore the CFTR protein defect.  
 
- Gastro-intestinal  
 
CF patients should maximize dietary intakes, taking a high-fat diet with appropriate pancreas 
enzyme replacement therapy (for pancreatic insufficient CF patients). All pancreatic 
insufficient patients should receive supplements of the fat-soluble vitamins. When nutritional 
failure occurs, patients can be fed by enteral tube.  
 
- Pulmonary  
 
Physiotherapy  
Physiotherapy is usually introduced soon after CF is diagnosed. Forced expiratory 
manoeuvres and autogenic drainage assisted by positive end expiratory devices are 
probably the most effective part of chest physiotherapy (106).  
 
Inhalation therapy  
Effective and efficient inhalation therapy is an important component of CF care. Recent 
advances in inhalation therapy consist of alternative inhaled formulations (e.g. dry powder 
inhalations) and improved nebulizer devices, with shorter delivery time and improved lung 
deposition of medication (107, 108). Different drugs with different therapeutic goals can be 
inhaled, including antibiotics, hypertonic saline and dornase alfa. The main current 
therapeutic agents and future therapeutic perspectives are shortly described below. Reviews 
on this topic can be consulted elsewhere (6, 109, 110).   
 
Inhaled tobramycin and colimycin are the most frequently used inhaled antibiotics in CF.  
Early studies with inhaled tobramycin, both low-dose (60-80 mg tid) (111, 112) and high-dose 
(600 mg tid) (113, 114) have shown an improved lung function and/or decreased 
hospitalisation rate in the treated patients. CF patients chronically colonized by P.  
aeruginosa on long-term nebulized tobramycin (300 mg bid, cycling 28 days on and 28 days 
off therapy) had a 10% increase in FEV1 and 36% reduction of IV antibiotic use compared to 
the placebo group (115).  
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Nebulised colistin achieves low systemic and high local concentrations in the lung, 
supporting its use in patients with P. aeruginosa infection (116). It is frequently used as an 
alternative or in addition to inhaled tobramycin in patients chronically infected by P. 
aeruginosa. A randomized one-month trial comparing tobramycin solution for inhalation with 
inhaled colistin found no difference in reduction of P. aeruginosa in culture, but a significant 
improvement in lung function in the inhaled tobramycin group only (117). This result may be 
explained by previous exposure to colistin and treatment with a 1MU rather than a 2MU dose.  
 
Nebulized human recombinant DNAse (dornase alfa, Pulmozyme®) is currently the most 
widely used mucolytic agent. It hydrolyzes the DNA present in sputum of cystic fibrosis 
patients, thereby reducing viscosity in the lungs and promoting the clearance of secretions. 
Daily inhalation improves lung function and reduces the frequency of infective exacerbations 
(118).  
Inhaled Mesna and N-acetylcysteine are sometimes used in CF patients, without studies to 
support clinical evidence (119). However, the interest in the use of N-acetylcysteine as anti-
oxidant drug, modulating inflammation in CF is growing (see future therapies p 26).  
Inhaled hypertonic saline (HS) increases airway epithelium hydration, thereby improving 
mucociliary clearance (120-122). Elkins et al. (118, 123) conducted a double-blind trial in 146 
CF patients, comparing inhalation with HS 7% bid with inhalation of normal saline 0.9% for 
48 weeks. Although the rate of change (slope) in lung function during the 48 weeks of 
treatment did not differ significantly between both groups (p = 0.79), the absolute difference 
in lung function between the two groups was significant. Furthermore, the HS group also had 
a significantly higher percentage of patients without exacerbations. As HS can cause 
transient air flow obstruction (124, 125), patients are better pretreated with beta 2 agonists. A 
recent Cochrane review  favours the use of HS (126).  
Short and long-acting beta-2 agonists can be beneficial both in the short and long term in CF 
patients with obvious bronchodilator responsiveness or bronchial hyperrresponsiveness 
(127). 
Inhaled corticosteroids are widely prescribed in CF. A recent Cochrane review concludes that 
evidence from trials is insufficient to establish whether ICS are beneficial in CF (128). CF 
patients with concurrent bronchial hyperresponsiveness may have some benefit of inhaled 
steroids (129) 
 
Antimicrobial treatment 
Antibiotics are the mainstay of treatment for pulmonary disease in CF and they are used for 
distinct situations. Antibiotics, either administered orally or intravenously, are used in the 
treatment of acute exacerbations, but also in attempts to eradicate early P.  aeruginosa 
infection (see Chapter II). Once patients are chronically colonized with P. aeruginosa, chronic 
maintenance antibiotics are taken in order to slow the decline in pulmonary function and to 
reduce the frequency of pulmonary exacerbations. Both inhaled (eg colimicin, tobramycin – 
see inhalation medication) and oral antibiotics (azithromycin) are used for this purpose.  
Maintenance treatment with azithromycin in CF patients chronically colonized with P.  
aeruginosa leads to a small but significant positive effect on lung function and less 
respiratory exacerbations (130-133). The exact mechanism of action of macrolides is 
unknown but is believed to be multiple. Both anti-infective and anti-inflammatory modes of 
action have been proposed to account for the efficacy of macrolides (134). Macrolides have 
an effect on formation of biofilms, as they inhibit the production of alginate and the 
expression of flagellin by P. aeruginosa  and modulate quorum sensing (135-139). 
Antimicrobial effects are augmented by excellent biofilm penetration and intracellular 
accumulation in P.  aeruginosa (140). It has been suggested that macrolides have an effect 
on reducing the sputum viscosity (141) and on P. aeruginosa adherence to respiratory 
epithelial cells (142). A recent study in P.  aeruginosa free children and adolescents with CF 
does not favour the use of azithromycin: treatment with azithromycin for 24 weeks did not 
result in improved pulmonary function (143). 
25 
 
Anti-inflammatory agents 
As airway inflammation starts early on in CF patients, it is logical to attempt to temper this 
ongoing inflammatory process. 
Oral corticosteroids have been shown to slow the progression of lung disease, but have 
unacceptable side effects for long-term use (144).  
Konstan et al. (145) demonstrated that high-dose oral ibubrofen led to a significant reduction 
in the rate of decline in FEV1 and fewer hospitalizations in CF patients with mild disease. 
Although ibuprofen has proven efficacy, it is not widely used because of its potential adverse 
effects, such as gastrointestinal bleedings  and the need of monitoring peak plasma 
concentrations, which is not a standard laboratory technique (146). 
 
Future therapies 
 
The CF scientific field is expanding rapidly and several new possible treatment options are 
currently being examined. The therapeutic drug pipeline is represented below 
(http://www.cff.org/research/DrugDevelopmentPipeline).  
Figure 7: CF therapies that are currently in development as of February 23, 2011. 
 
 
 
 
 
 
  
 
 
 
PRE- PHASE PHASE PHASE      TO 
CLINICAL 1 2 3     PATIENTS 
Gene therapy  
 
CFTR modulation 
 
 
Restore airway surface liquid 
 
 
 
Mucus alteration 
 
Anti-iflammatory 
 
 
 
 
 
Anti-infective 
 
 
 
 
 
 
Transplantation 
 
Nutrition  
 
26 
 
These future therapies include:  
 
New inhaled antibiotic treatments:  
Aztreonam lysine for inhalation (Cayston®) has shown in a Phase III study in CF patients 
colonized with P. aeruginosa a significant improvement in respiratory symptoms and FEV1 in 
the treatment group compared to the placebo group (147, 148). Cayston® received FDA 
approval in the US and EMA approval in Europe and became available to patients in the US 
in March 2010. In Belgium, we are awaiting reimbursement.   
Tobramycin inhalation powder (TIP) was developed as an alternative to nebulized 
tobramycin (107). A Phase III trial has completed enrollment.  
 
 
Other inhalation therapies:  
Denufosol is a novel ion channel regulator designed to correct the ion transport defect and 
increase the overall mucociliary clearance in cystic fibrosis lung disease by increasing 
chloride secretion, inhibiting sodium absorption, and increasing ciliary beat frequency in the 
airway epithelium independently of cystic fibrosis transmembrane conductance regulator 
genotype. Patients who received denufosol demonstrated a significant increase in pulmonary 
function parameters compared to the placebo group (149). The results of a Phase 3, 
randomized, double-blind, placebo-controlled, 24-week trial in 352 CF patients with normal to 
mildly impaired lung function were published recently (150). A significant mean change in 
FEV1  (p = 0.047) from baseline to week 24 in the patients inhaling denufosol 60mg 3 times a 
day compared with the placebo group was observed. A 48-week trial involving 466 CF 
patients however, showed that denufosol failed to meet its primary endpoint in generating a 
significant improvement in FEV1. As a consequence Inspire Pharmaceuticals, the company 
producing denufosol decided to stop further investigations on this drug.  
Inhaled dry powder mannitol (Bronchitol®) improves hydration and surface properties of 
sputum in CF patients (151), thereby improving mucociliary clearance. It has been shown to  
increase mucociliary clearance and FEV1 (152). Phase III trials are ongoing.  
 
Anti-inflammatory agents 
The interest in the use of N-acetylcysteine, an anti-oxidant drug replenishing glutathione 
levels in neutrophils and modulating inflammation in CF is growing (153-155). Furthermore, 
N-acetylcysteine has shown in in vitro experiments in CF airway epithelial cells to increase 
chloride efflux, thereby improving hydration of mucus (156). A Phase 2 study on the efficacy 
and safety of high doses oral N-acetylcystein in CF patients failed to demonstrate an effect 
on clinical or inflammatory parameters after 12 weeks. However, extracellular glutathione in 
induced sputum tended to increase on high-dose N-acetylcysteine (154). A Phase 2b multi-
center trial completed enrollment in 2010. 
 
Pseudomonas vaccination 
Early studies of polyvalent Pseudomonas vaccines did not show a decrease in P.  
aeruginosa colonization in the vaccinated group  and may have even predisposed some 
patients, once infected with P. aeruginosa,  to a more severe pulmonary disease (157). A 
recent trial appeared to be more successful:  Lang et al. (158) analyzed the 10-year follow-up 
data of 26 vaccinated CF patients, annually receiving a polysaccharide-exotoxin A conjugate 
P. aeruginosa vaccine and demonstrated that the time to infection with P. aeruginosa was 
longer and that the frequency of chronic infection with P. aeruginosa was significantly 
reduced in the vaccination group (32% of the vaccinated patients versus 72% of the control 
patients). In a prospective 2-year trial with a P. aeruginosa flagella vaccine (159), P. 
aeruginosa infections were documented in 37 of 189 vaccinated subjects versus 59 of 192 
control subjects (p = 0.02). More recently published vaccine trials investigate alternative 
routes of administration of the vaccine in order to induce local immunity in the lung. For 
example, Bumann et al. (160) detected that only nasal and oral vaccinations, but not 
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systemic vaccination with a P. aeruginosa outer membrane porin vaccine resulted in a  
significant rise of IgA and IgG antibodies in the lower airways. Larger trials are needed to 
further validate the clinical benefit of these vaccines. 
 
Gene therapy   
Since the cloning of the CF gene in 1989, 25 Phase I/II clinical trials involving approximately 
420 CF patients have been carried out, using a variety of viral and non-viral gene transfer 
agents. A gene therapy-based treatment however has not yet been developed (161). Barriers 
to effective gene transfer therapy are difficulties to deliver the vector to the cell, poor 
efficiency (162, 163), limited duration of gene expression and significant immune and 
inflammatory response to the virus-derived vector (162, 164, 165).  
 
Mutation-specific therapies  
Mutation-specific chloride channel correction pharmacotherapy is being developed at present 
and is a rapidly expanding area of research. These therapies are designed to correct or 
increase the function of the defective CFTR protein: “correctors” correct mutated CFTR 
function, “potentiators” improve channel gating.  Some examples of these new therapeutical 
agents are described below:  
In patients with one or more stop codon mutations, PTC 124 (Ataluren®) selectively induces 
read-through of premature stop codons. It has been studied in Duchenne muscular dystrophy 
and CF patients with a stop codon mutation (class I mutation) (166, 167). Its high oral 
bioavailability makes this product a promising medicine. In a Phase II study, oral 
administration of PTC124 reduced  the epithelial electrophysiological abnormalities as 
assessed by transepithelial nasal potential difference (168, 169) and there was a trend 
toward improvements in pulmonary function (170).  Phase III studies in CF completed 
enrollment in fall 2010. 
In vitro studies have demonstrated that VX 770 is a CFTR potentiator that increases CFTR-
mediated chloride transport (171). Accurso and colleagues recently published the results of a 
double-blind, placebo-controlled multicenter Phase 2 trial on the effect of orally administrated 
VX-770 in CF patients with at least one copy of the G551D mutation (172). They 
demonstrated improvements in both biological measures of CFTR function (nasal potential 
difference and sweat chloride) and pulmonary function measures (FEV1). In February 2011, 
Vertex Pharmaceuticals, the company that developed VX 770, released promising results of 
a Phase 3 clinical trial of VX-770 in CF patients age 12 and older who carry at least one copy 
of the G551D mutation. In March, the company also released positive results from an 
ongoing Phase 3 clinical trial of VX-770 in children age 6 to 11 with the G551D mutation. 
In the study of VX-770 in adults, patients who took the drug, compared to those on placebo, 
showed marked improvements in lung function (10 percent) and other key indicators of the 
disease, including sweat chloride levels, likelihood of pulmonary exacerbations and body 
weight. In the trial of VX-770 in young children, those who received the drug showed similarly 
significant improvements in lung function (12.5 percent) and in other key measures of the 
disease, including body weight and sweat chloride levels (www.vrtx.com). 
The results of a phase II randomised placebo controlled clinical trial of 4 doses of the CFTR 
corrector VX-809 in CF patients homozygous for F506del CFTR mutation were presented at 
the NACFC 2010 by Clancy et al. The investigators noted a dose-dependent decrease in 
sweat chloride concentration but no effect on nasal potential differences nor on clinical 
parameters (FEV1 and quality of life questionnaire) on day 28. 
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9. Pathogenesis of pulmonary disease and P. aeruginosa  infection in cystic fibrosis  
The mechanisms underlying CF lung disease are complex and not completely understood. 
There are several hypotheses as to how the CFTR defect causes the clinical picture of CF 
lung damage, of which the hallmarks are the intensive neutrophilic airway inflammation and  
the propensity to become infected with only a limited number of bacteria, non-pathogenic in 
the normal host. Some of these hypotheses will be outlined below, with the focus on 
pathogenesis and persistence of P. aeruginosa infection. In this chapter, the different 
theories are somewhat artificially classified into compositional, immunological, inflammatory 
and adherence hypotheses (figure 10).  It is important to acknowledge that these hypotheses 
are not mutually exclusive. It is beyond the scope of this thesis to discuss all theories (with 
sometimes conflicting results), extensive reviews on this topic can be consulted elsewhere 
(173-180).   
 
Defense strategies in the lungs of healthy individuals  
 
In healthy individuals, host bacteria entering the lungs are cleared rapidly, without the 
initiation of an inflammatory response, by an array of host defence strategies, both 
mechanical (i.e. mucociliary clearance) and immunological.   
 
Mechanical: Mucociliary clearance (MCC) is mediated by the airway surface liquid (ASL) 
(figure 8). The ASL lies on top of the epithelial surface and consists of two layers: a mucus 
layer, generated by secreted mucins  and a periciliary liquid layer (PCL), being  a poly-
anionic water layer. The mucus layer entraps inhaled particles and pathogens, this entrapped 
material is cleared through the coordinated beating of cilia, moving the mucus blanket over 
the periciliary liquid layer. In normal airway epithelia Cl- secretion (mediated by CFTR- and 
Ca2+- Cl- -channels)  and Na+ absorption (mediated by the epithelial Na+-channel (ENaC)) are 
coordinated to maintain ASL at a depth that allows cilia to beat efficiently and to move the 
mucus blanket over the periciliary liquid layer (181).  
Immunological: The resident macrophages and antimicrobial peptides, such as lysozyme and 
lactoferrin, protect against invading pathogens.  
 
Figure 8: the airway surface liquid (ASL) 
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Theories linking the altered CFTR function to the increased inflammation and early 
infection in CF lungs  
 
- Compositional theories ( figure 9)  
Low volume hypothesis  
In the low volume hypothesis, defective CFTR results in increased sodium and water 
absorption, depleting the volume of ASL and of the mucus layer, within which cilia are unable 
to beat efficiently (182-185). Mucociliary clearance is impaired and  the inhaled particles, 
bacteria and viruses become trapped in the viscous ASL and the mucus transport rates are 
reduced. Failure to clear inhaled environmental particles and irritants triggers release of pro-
inflammatory chemokines, such as IL-8, from airway epithelia and/or macrophages patrolling 
airway surfaces. The cytokines become concentrated in the thickened mucus, recruit 
neutrophils into the airway lumina, and trigger airway inflammation even in the absence of 
bacteria.  
High salt hypothesis  
The high-salt hypothesis claims that in the absence of functional CFTR, excess sodium and 
chloride are retained in airway surface liquid (186, 187). The increased concentration of 
chloride in the periciliary layer disrupts the function of important innate antibacterial defense 
proteins, such as human β-defensin 1, lysozyme and lactoferrin, allowing bacteria, that would 
be cleared by normal airways, to persist in lungs (188). Although in vitro data have shown 
that the high salt content in CF airways disables these defense molecules (186), in vivo data 
demonstrated that ASL electrolyte levels are not different between CF and healthy airways 
(189), refuting this hypothesis.  
 
Figure 9: low volume and high salt hypothesis (6) 
 
 
30 
 
 (A) The low-volume hypothesis postulates that normal ASL (A1) has salt levels approximately equal to plasma. In 
CF (A2), the removal of CFTRs inhibition of epithelial sodium channels (EnaC) results in abnormally elevated 
isotonic fluid absorption, which depletes the ASL and leads to reduced mucociliary clearance. Key features of the 
low-volume model are the parallel pathway for Cl- via shunt pathway(s) and inhibition of ENaC via CFTR.  
(B) The high-salt hypothesis postulates that normal ASL has low levels of salt as a result of salt absorption in 
excess of water (B1). Even though the epithelium is water permeable, salt is retained in thin surface films by 
some combination of surface tension impermeant osmolytes. In CF (B2), salt is poorly absorbed resulting in 
excessively salty ASL that inactivates endogenous, salt-sensitive antimicrobial peptides. Key features of the high-
salt model are: the lack of an appreciable shunt Cl- conductance, central importance of CFTRs channel role, no 
specific role for inhibition of ENaC by CFTR, and a switch from isotonic volume absorption to hypertonic salt 
absorption as the surface layer thins and traps residual water. 
 
 
- Immunological theories: 
 
There are some indications that CFTR alterations lead to decreased local immunity in CF 
airways. These failures of local innate immunity might be risk factors for CF airway infections.  
There are several resports indicating that the oxidative killing is impaired in CF patients:  
In the bronchi, the highly viscous mucus generates a microaerobic milieu which may become 
anaerobic by a rapid oxygen consumption by pathogens such as P. aeruginosa (190). 
Consequently, the generation of reactive oxygen species (ROS) by neutrophils and other 
cells is abolished and bacterial killing impaired   The microaerobic/anaerobic environmental 
conditions on the respiratory epithelium allow microbial pathogens, intrinsically resistant to 
non-oxidative killing or capable to change their phenotype to become rapidly resistant to non-
oxidative killing, to persist in airways of individuals with CF. On top of that, Moskwa and 
colleagues (191) have demonstrated that a diminished transepithelial hypothiocyanite (SCN-) 
transport exists in CF airways, resulting in a defective killing of bacteria through the oxidative 
defense mechanism by means of ROS. Furthermore, according to the high-salt hypothesis, 
antibacterial peptides in the ASL are inactivated by the high salt concentration. In addition, 
there is accumulating evidence that expression of nitric oxide (NO) synthase is regulated by 
CFTR. Low levels of NO synthase are present in CF airways, resulting in low levels of nasal 
and exhaled NO (192). As NO has certain antibacterial and pro-inflammatory properties, the 
low levels could have,at least partly, a role in the predisposition to infection.  
 
- Inflammatory theories:  
 
Hallmark of CF airway disease is the intense neutrophilic inflammation, starting early on in 
life. Studies have attributed a central role of Toll-like receptors (TLRs),  nuclear factor κB 
(NF-κB) signalling pathway and neutrophil elastase in the development of CF lung disease.  
The adhesion of mucus to the epithelium surface brings epithelial cells into the first line of 
host defense against colonizing bacteria. Invading bacteria display pathogen-associated 
molecular patterns (PAMPs), which are recognized by TLRs on the airway epithelium and 
their activation results in a pro-inflammatory response, leading to activation of downstream 
signalling cascades such as NF-κB and production of pro-inflammatory cytokines and 
chemokines. Each TLR has the ability to recognize and discriminate a specific PAMP present 
on invading pathogens. The most studied TLRs in CF are TLRs 2, 4 and 5. 
Heterodimerization of TLR2 with TLR1 or TLR6 results in the recognition of microbial 
components from the cell wall of Gram-positive bacteria, such as lipoproteins, peptidoglycan 
and lipoteichoic acid, whereas TLR4 is involved in the detection of lipopolysaccharide (LPS) 
and TLR5 with flagellin, which are both found in Gram-negative bacteria. LPS, which is found 
on Ps. aeruginosa, plays a major role in producing the chronic infection seen in the CF 
airways (178). Activation of any TLR results in a Th1 innate immune response, which is 
characterized by NF-κB activation and the release of pro-inflammatory mediators.NF-κB is 
one of the key regulating transcription factors of genes that are involved in inflammation and 
immunity. Activation of the NF-κB pathway in the CF airways leads to enhanced secretion of 
IL-8 and other chemokines by the airway epithelial cells (193-198). IL-8 is the principal 
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neutrophil chemoattractant in the CF lung (199), attracting neutrophils, which on their turn 
produce elastase. Extracellular neutrophil elastase has several roles: it cleaves CXCR-1, a 
chemokine receptor, from the neutrophil cell surface, thereby disarming neutrophils of their 
antibacterial capacity. The released CXCR-1 stimulates IL-8 production by the airway 
epithelial cells, thereby initiating a feedback circuit that amplifies neutrophil recruitment within 
the CF airways and amplifying inflammation (200). Elastase can also induce mucin 
overproduction by airway glands, potentiating obstruction (201). It can cleave scavenger 
receptors on macrophages and epithelial cells, inhibiting clearance of apoptotic neutrophils. 
Some studies also established that CF airways are relatively deficient  in counter-regulatory 
molecules such as IL-10 and NO. Consequently, a lack of inhibition on the NF-κB activity 
results in prolonged and excessive production of inflammatory mediators (202-205).  Despite 
the fact that the link between NF-κB signaling and inflammatory activation is established, the 
precise “activator mechanism” by which the deficient CFTR leads to an elevated NF-κB 
activation in the CF airway remains to be elucidated.  Discussion continues whether 
inflammation is  intrinsically inherent to CFTR defect or secondary to infection. 
 
Studies favouring the theory of an intrinsically increased inflammation in CF:  
Some studies have found increased numbers of inflammatory cells and IL-8 in BALF from CF 
patients with either mild disease symptoms or in the absence of demonstrable 
microorganisms (205-211). Many studies have found that CF airway epithelial cells in culture 
have constitutively active NF-κB and upregulated expression and secretion of IL-8 and other 
inflammatory mediators (207, 208, 211-215).  This apparent inherent inflammatory state may 
be further stimulated by the presence of P. aeruginosa (211, 216), though not always (213). 
 
Studies favouring the theory of inflammation resulting from infection:  
Other authors hold the opinion that early infection in CF is  the likely explanation for the 
enhanced inflammatory responses in CF lungs. In vivo measurements of inflammatory 
mediators in BAL fluids showed that increased inflammation in CF followed bacterial 
infections (38). Recent studies using terminal restriction fragment length polymorphism 
analysis (RFLP) of sputum from both adult (217) and pediatric (218) CF patients have shown 
many  bacterial species that have not been previously identified in CF. It therefore seems 
possible that previous in vivo studies that observed inflammation in the apparent absence of 
infection may have suffered from low sensitive methods for bacterial detection. 
 
- P.  aeruginosa adherence/ingestion theories  
 
These theories give some clue as to why CF lungs are especially vulnerable to infections 
caused by P. aeruginosa.   
 
The adherence hypothesis  
This theory alleges that the defective CFTR protein causes an increased availability of 
receptors for P. aeruginosa. P. aeruginosa possesses several different classes of adhesins 
(e.g. pili and flagellae) to bind to receptors on cell surfaces. One of these binding sites, the 
asyalated glycolipid GM1 (aGM1) is present in increased abundance on the surface of CF 
respiratory epithelial cells, allowing an increased binding of P. aeruginosa to CF cells  (219, 
220). Pseudomonads also produce neuraminidase, which cleaves sialic acid off glycolipids, 
thereby increasing the amount of aGM1 (221). In addition, adherence of P. aeruginosa to this 
receptor leads to a NF-κB-mediated increase in expression of the pro-inflammatory cytokine 
IL-8, with ensuing increase of the inflammatory cycle.  Recently, Teichgraber et al. (222) 
detected an abnormal accumulation of ceramid (a sphingomyelin component of biological 
membranes) in the lungs of CFTR-deficient mice and in epithelial cells from CF patients. As 
a consequence, the rate of cell death increases in the respiratory epithelial cells, resulting in 
the formation of DNA deposits on the respiratory epithelium, facilitating bacterial adherence 
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of P. aeruginosa. Ceramide accumulation also provokes a pro-inflammatory status with an 
increased synthesis and release of cytokines and a subsequent recruitment of macrophages 
and neutrophils. This phenomenon precedes  bacterial infection. How mutated CFTR 
mediates ceramide accumulation is still discussed. 
 
 
The ingestion hypothesis  
In this hypothesis, supported by Pier et al. (223), CF respiratory epithelial cells are less 
capable than normal cells to ingest P. aeruginosa. In contrast with the former hypothesis, 
Pier et al. hypothesize that the wild type CFTR is a receptor for P. aeruginosa. Binding of P. 
aeruginosa to the wild type CFTR  airway epithelium results in phagocytosis and clearance 
by desquamation (223, 224). Defective CFTR consequently leads to reduced P. aeruginosa  
binding, resulting in reduced P. aeruginosa clearance from the CF airway.  
Darling et al. (225), in contrast, proposes that internalized P. aeruginosa may play an 
important role in the pathogenesis of infection and that, by allowing greater internalization 
into epithelial cells, mutant CFTR results in an increased susceptibility of bronchial infection 
with this microbe.  
 
 
Figure 10: Hypotheses on pathophsiology of CF airway disease  
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Chapter II: PSEUDOMONAS  AERUGINOSA  
Introduction:  
 
CF patients can get infected by P. aeruginosa early on in life and the prevalence of  
P. aeruginosa in respiratory cultures increases with age, from 10–30% at ages 0–5 years to 
80% at ages 25-34 years (US data – Chapter I figure 4 )(12). In Belgium, prevalence rises 
from <10% in the children < 1year of age to nearly 70% at ages 25-34 years according to the 
2008 data (Chapter I – figure 6) (14). P. aeruginosa infection in CF patients takes its course 
in distinct stages. After treatment of a first ever isolate of P. aeruginosa, patients may go 
through different episodes of colonization (intermittent colonization), preceding chronic 
colonization by months to years, eventually resulting in chronic infection (6, 49, 226).  
P. aeruginosa strains causing early infection usually have a nonmucoid phenotype, are 
present in low bacterial density and are relatively antibiotic susceptible. Over time, the 
distinct microenvironment in the CF airways allows selection of P. aeruginosa uniquely 
adapted for chronic, persistent infection. These organisms are mucoid, form biofilms, 
become increasingly antibiotic-resistant (227), are present at high density, and are virtually 
impossible to eradicate (228, 229).  In this chapter, the origin of P. aeruginosa in CF patients, 
the evolution from initial to chronic infection and non-mucoid to mucoid P. aeruginosa in CF 
patients, the consequences of chronic colonization by this pathogen and finally the treatment 
of P. aeruginosa in CF patients will be discussed.  
 
P. aeruginosa: natural habitat and survival: 
 
P.  aeruginosa  is an ubiquitous organism: it has been isolated from soil (230, 231), from 
plants and vegetables (231) and from water samples from creeks, rivers (232) and other 
water sources such as drinking water (233). Sewage frequently harbors P. aeruginosa.  
P. aeruginosa is not a marine organism, probably because the high salt concentrations inhibit 
its growth. P. aeruginosa is rarely isolated from healthy humans with only up tot 7% of 
healthy humans carrying P. aeruginosa in the throat, nasal mucosa or the skin (234), and 
1.2% to 2.3% of healthy individuals harboring P. aeruginosa in the intestines (235-237).  
Animal experiments have shown that the addition of penicillin to drinking water leads to 
intestinal colonization by P. aeruginosa (238) and accordingly, the use of antibiotics in 
hospitalized patients increases considerably the incidence of P. aeruginosa -positive stools 
(239). Carriage rates of P. aeruginosa in stool as high as 24% have been reported in 
hospitalized patients (234, 240). 
P. aeruginosa is tolerant to temperatures as high as 45 to 50 °C an d sensitive to desiccation 
and light and hence short-lived in aerosols and on dry surfaces (241). However, P. 
aeruginosa strains may survive considerably longer in the presence of protein and other 
organic material, e.g. in sputum. Mucoid P. aeruginosa strains survive longer than non-
mucoid strains and strains suspended in sputum of CF patients can survive on dry surfaces 
for as long as 8 days (242, 243).  
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Origin of P. aeruginosa in CF patients  
 
Numerous studies have attempted to identify the initial source of P. aeruginosa in CF 
patients. Both transmission from the natural environment, home and hospital environment 
and from other CF patients has been investigated. This chapter gives an overview on the 
current knowledge on possible sources and transmission of P. aeruginosa to CF patients.  
 
 
•  Patient-to-patient transmission:  
 
Transmission of P. aeruginosa from one CF patient to another CF patient has been well 
studied. The so-called “Danish experience” is the first documented observation of patient-to-
patient transmission and described the effect of preventive measures to limit the spread of P. 
aeruginosa among CF patients.  In the 1980s, after the observation that one epidemiological 
P. aeruginosa strain predominated in CF patients in the Danish CF centres  (244, 245), 
studies were undertaken to identify routes of cross-infection. The CF ward was found to be 
massively contaminated by P. aeruginosa of the same type as those cultured from the 
patients (243) and it was shown that patients could spread P. aeruginosa when coughing. 
Furthermore, the observation that CF patients treated outside the centre had a lower 
prevalence of chronic P. aeruginosa infection and contracted the infection later (246) 
confirmed the suspicion of patient-to-patient transmission of P. aeruginosa.  Hoiby and 
Pedersen (244) calculated that the risk of cross infection increased with “contact density”, i.e. 
the number of days a noninfected CF patient spent at the CF centre. Based on these results, 
preventive measures were introduced: P. aeruginosa infected patients were segregated from 
non-infected patients in separate wards and on separate days in the outpatient clinic, and 
improved hygienic measures were undertaken in the clinic (243). After the introduction of 
cohort isolation in the CF centre, an epidemic spread of multi-resistant P. aeruginosa strain 
was observed in the CF ward for patients with chronic P. aeruginosa infection (246). Further 
development of this epidemic was immediately stopped by establishing a third cohort for the 
patients harbouring the multi-resistant strain. As a result of the segregation measures and 
the improved hygiene the yearly incidence of new chronic P. aeruginosa infection dropped 
from 17% in 1976-1980 to 3% in 1986-1987 (247). Later on, the existence of patient-to-
patient transmission was confirmed by genotyping of P. aeruginosa (248, 249).  
 
Different conclusions on the degree of transmissibility of P. aeruginosa have been drawn 
from two molecular epidemiological studies from two large centres without segregation 
policies in Australia (250) and Canada (251). The Australian cross-sectional study found a 
widespread clone of P. aeruginosa in 55% of 118 infected patients in a paediatric CF clinic. 
In contrast, the Canadian longitudinal study, run over two decades, showed a low risk of 
patient-to-patient spread among 174 patients, except for patients with prolonged and close 
contacts, such as siblings. A non-exhaustive overview of the studies supporting the positions 
of both groups can be consulted in Table 1.
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Table 1: studies on patient-to-patient transmission of P. aeruginosa.  
Author year (ref) Number of patients/sputum samples/isolates Genotyping method % of identical isolates Remarks 
Studies indicating  the existence of highly transmissible P. aeruginosa strains  
Cheng 1996 (252) 92/92/NR PFGE 60 Liverpool strain 
Liverpool, UK 
Jones 2001(253) 154/154/NR PFGE 14 
Manchester, UK 
Edenborough 2004 (254) 43/407/NR PFGE  16/23 Liverpool strain/Sheffield strain 
Sheffield, UK  
Scott 2004 (255) NR/NR/ 849  PFGE  11/10/1,7 Liverpool (15 centres), Midlands (9 centres),  
UK other strain (8 centres) 
Armstrong 2002 (250) 118/118/NR PFGE/fAFLP  55 Melbourne strain, also in 5 distant centres (256) 
Victoria, Australia 
O'Carroll 2004 (257) 100/100/NR PFGE  59 Largest cluster: 39 patients; 8 patients Melbourne strain 
Brisbane, Australia  
Studies indicating the existence of a limited patient-to-patient transmission risk of P. aeruginosa  
Speert 2002 (251) 174/NR/NR RAPD/PFGE  12/10 157 genotypes of which 123 unique ones 
Vancouver, Canada  48% and 42% of shared Pa strains transiently present  
Tubbs 2001 (258)  72/NR/NR PFGE  NR 10 clusters (4 sibling pairs). Largest cluster: 5 patients 
North Staffordshire, UK  
Da Silva Filho 2001 (259) 38/65/86 RAPD 0 
Sao Paulo, Brazil  
Van daele 2006 (260) 213/213/910 RAPD/fAFLP 31 163 genotypes. 16 clusters (66 patients) 
7 CF centres , Belgium  Largest cluster: 12 patients 
Abbreviations : see list of abbreviations p. 4-5  
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Reports on highly transmissible strains of P. aeruginosa mainly originate from the UK and 
Australia (250, 252-257).  
Furthermore, data suggest that cross-infection with these highly transmissible strains has 
occurred between CF centres both within England and within Australia (255, 256).  
Some highly transmissible P. aeruginosa strains are more virulent: The “Melbourne” 
epidemic P. aeruginosa strain caused 5 deaths in young CF children (250) and CF patients 
who were infected with a transmissible strain had an increased number of exacerbations and 
days of intravenous antibiotics and hospital days than those with sporadic P. aeruginosa 
(261). In a retrospective study, 12 patients infected with the Liverpool epidemic strain had a 
greater loss of lung function and deterioration in BMI than those not chronically infected 
(262).  In an 8-year prospective study of the clinical impact, Jones et al. (263) concluded that  
infection by transmissible P. aeruginosa does not increase mortality but is associated with an 
increased healthcare utilization and antibiotic use. This increased virulence does not apply to 
all  epidemic strains of P. aeruginosa: De Vrankrijker et al. (264) did not detect unfavorable 
clinical outcome (pulmonary function, nutritional status, hospitalization days) among 40 CF 
patients, infected by the highly prevalent Dutch  
P. aeruginosa clone ST 406.  
In contrast with the reports on highly transmissible strains, other groups (including ours) 
observed a limited risk of patient-to-patient spread of P. aeruginosa even when patients were 
not segregated according to P. aeruginosa colonization status. Patient-to-patient spread in 
these studies was limited to prolonged close contact, such as between siblings and close 
friends (251, 258-260). 
 
Segregation of patients has been shown in several CF centres to prevent cross-infection 
with P. aeruginosa (247, 265). In most studies however, attempts of limiting P. aeruginosa 
infection has not only been made by segregating P. aeruginosa infected patients from not 
infected patients, but also by implementation of hygienic precautions. Effects of segregation 
itself on patient-to-patient spread of P. aeruginosa is difficult to assess. Nevertheless, some 
observations support  the effect of segregation policy on the acquisition of P. aeruginosa.  
After the observation that in 4 years time (1983-1986) the prevalence of P. aeruginosa 
infection had risen from 37% (33 patients) to 60% (104 patients) and that 12 out of the 40 
patients newly colonized by P. aeruginosa had acquired P. aeruginosa at CF recreation 
camps, clinics or rehabilitation centres, hygienic and segregation precautions were 
introduced at the CF clinic in Hannover Germany. This led to only a single episode of 
nosocomial transmission of P. aeruginosa during the subsequent 2 years (266). 
Following the identification of the Melbourne epidemic P. aeruginosa strain, cohort 
segregation according to P. aeruginosa culture status and genotype was introduced. To 
determine if these strategies had interrupted cross-infection within the clinic, patients from 
the initial study were followed prospectively (265).  Three years after the introduction of 
cohort segregation, the epidemic strain prevalence had decreased from 21%  to 14%  
(p = 0.03). Farrell and coworkers (267) in Wisconsin, USA reported later acquisition of  
P. aeruginosa among newly diagnosed CF patients who were segregated from P. aeruginosa 
colonized patients compared with CF patients at another outpatient clinic where no 
segregation measures were taken. McKay and colleagues (268) in Sydney, Australia, 
introduced segregation for children under five from older patients and from P. aeruginosa 
positive peers. They compared data on P. aeruginosa acquisition before (1999-2002) and 
after introduction of segregation (2004-2007). There was a significant decrease  in the 
acquisition of mucoid but not in acquisition of  non-mucoid P. aeruginosa after segregation, 
indicating that mucoid P. aeruginosa were likely to be transmitted from other patients, 
nonmucoid P. aeruginosa however must come from other (environmental?) sources.  
 
Interpretation of the different studies on patient-to-patient transmission of P. aeruginosa are 
somehow hampered by several factors. In the first place, no agreement or even discussion 
exists on the definition of a “higly transmissible” strain: from what percentage of shared  
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P. aeruginosa in a CF community on is a strain called “highly transmissible”? This results in 
different conclusions of authors on sometimes comparable results: e.g. in the study of Speert 
et al. (251), the largest clone is present in 12% of the patients, nearly the same percentage 
(14%) is seen in the study of Jones et al. (253). Authors however come to different 
conclusions and different degrees of alertness:  
Speert et al. (251): “It appears that prolonged close contact, such as occurs between siblings,  
is necessary for patient-to-patient spread. Considering these observations, we do not 
recommend segregation of patients with CF on the basis of their colonization status with P. 
aeruginosa.” 
Jones et al (253): Cross-infection by a multiresistant P aeruginosa strain has therefore 
occurred in patients attending our cystic fibrosis centre. We recommend microbiological 
surveillance in other cystic fibrosis centres.  
Another example of different interpretation of results holds true for Fluge et al (269). Although 
45% of the 60 Norwegian CF patients studied over a 5 year period (1994-1998) had a 
common P aeruginosa genotype, authors conclude:  “Our results  indicate that cross-
infection with P aeruginosa between CF patients has occurred”; but also: “The advisory 
board of the Norwegian cystic fibrosis society has decided that segregation should not be 
advocated, except in cases of infection with multiresistant strains. Hygienic measures have 
been introduced and CF patients and health care personnel are now aware of the possibility 
of cross-infection. We believe that our new guidelines will be sufficient in preventing cross-
infection with P aeruginosa”. 
 
Conclusion: Several studies have clearly demonstrated the existence of patient-to-patient 
spread of P. aeruginosa between CF patients. Conflicting data however exist on the extent of 
this spread: does it only result from longstanding and close contact between CF patients or is 
P. aeruginosa highly transmissible?  Previous studies have supported the position of both 
groups, indicating the difficulty of making general statements about this highly diverse and 
adaptable pathogen. It seems reasonable that both opinions are correct and that different 
strains of P. aeruginosa circulate: some of low and other of high transmissibility. As a result 
of these studies on patient-to-patient transmission of P. aeruginosa, segregation measures 
according to P. aeruginosa status have been advised in the European consensus guidelines, 
but not (yet) in the US guidelines.  
 
• Environment-to-patient transmission  
 
There are some indications that the environment might be the initial source of P. aeruginosa 
in CF patients. First of all, P. aeruginosa is widely present in the natural environment in soil, 
plants and water. Initial isolates from infants and young children with CF usually display an 
“environmental phenotype” (49): they are nonmucoid, fast growing and relatively susceptible 
to antibiotics. Romling and colleagues (270) demonstrated that the most prevalent clone in 
CF patients was also frequently isolated in aquatic environment and in various spatially and 
temporally separated habitats. In addition, the environmental origin of P. aeruginosa in CF   
patients is suspected by the observation that young CF children can be protected from the 
acquisition of mucoid P. aeruginosa by patient segregation and that  the acquisition of non-
mucoid P. aeruginosa is likely to be from environmental sources, as the rate of acquisition of 
non-mucoid P. aeruginosa did not decrease after segregation (268).  
The contamination with P. aeruginosa especially  in health care settings and to a lesser 
degree in non-health care settings and possible transmission from these environments to the 
CF patients has been studied.  
 
Studies on the presence of P. aeruginosa in CF health-care settings  
P. aeruginosa has been recovered from numerous environmental sources in both in- and 
outpatient CF healthcare settings, e.g. sinks, soap, baths, toys, tables, brushes, cloths, and 
38 
 
air (243) tap-water, sinks, wash-basins and creams (271), pulmonary function machines 
(251), hands of health care workers and CF patients (242, 243, 251).  
A lot of studies extend on the contamination of CF clinics (both in- and outpatient) with P. 
aeruginosa, some of these also try to link environmental P. aeruginosa genotypes with P. 
aeruginosa genotypes encountered in the CF patients. These studies, outlined in Table 2, 
demonstrate that especially the sinks in CF wards can be contaminated by P. aeruginosa 
(242, 243, 271-274). Sometimes, environmental P. aeruginosa strains were identical to the 
CF patient P. aeruginosa strains, transmission  however was difficult to prove (243, 272-
274).  
An interesting observation on possible environment-to-patient transmission was  made by 
Doring et al. (242). The authors performed a 4 week prospective study of P. aeruginosa 
strain transmission in a pediatric CF ward in Tubingen, Germany.  Samples were taken 
weekly from sink drains, toilets, baththubs and showers in the CF ward and from hands of 
the hospital personnel. Cultures form sputum, throat, nose and anus were taken weekly from 
14 CF patients admitted to the CF ward during that time period . P. aeruginosa strains were 
compared by means of PFGE. One out of the five CF patients not colonized by P. 
aeruginosa entering the ward became positive for an environmental P. aeruginosa strain one 
week after entering the ward and remained positive for the following 3 weeks during his stay 
on the ward. Strain transmission from the environment to this patient was highly probable in 
this case. The authors suggested that transmission occurred through the personnel, as the 
environmental strain was detected in a distant washbasin one week before it was isolated 
from the patient, although this could not be proven.  
Conclusion: The different studies on the prevalence of  P. aeruginosa in CF health care 
settings demonstrate that especially sinks are heavily contaminated. Genotypes of 
environmental P. aeruginosa sometimes matched patient strains and in one patient 
environment-to-patient transmission was strongly suspected.  
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Table 2: studies on the prevalence of P. aeruginosa in healthcare settings.  
 
Reference   Geographical location Sampling site Sample Number % positive for  Number of isolates identical 
     
P. aeruginosa  to patient isolates 
Zimakoff  1983 Copenhagen, Denmark CF IP & OP wards Dry surfaces 258 2,7 
(243) CF IP & OP wards Sinks/baths 43 30 8 
non-CF IP ward Dry surfaces 72 0 
non-CF IP ward Sinks/baths 27 11 0 
Speert 1987 Vancouver, Canada  CF IP ward Dry surfaces 385 1.3   
(272) 
Bathroom/Patient room 
sinks 126 11 5 
Hands personnel 43 0 
Bosshammer  1995 Hannover, Germany  CF IP & OP wards Bathroom 328 8,8 NR 
(271) Sink drains (35) 280 63  of sink drains 
Water taps (35) 280 31 of water taps 
Dry surfaces NR 0 
Hands of personnel NR 0 
Doring  1996 Tubingen, Germany  CF IP ward Hands of personnel 79 14 1 
(242) Sink drains 24 87,5 
Festini  2007 Florence, Italy CF OP ward Dry surfaces in 5 rooms 230 NR 
(273) Sinks + sink drains (5) 230 44,3 (sinks) - 21-71 (sink drains)    
All samples 460 22.8 19/21 investigated strains  
Panagea  2005 Liverpool, UK CF IP & OP ward Bathroom 22 73 1 "Liverpool" strain 
(274) Dry surfaces 22 13,6 All 3 " Liverpool" strains, all from respiratory equipment 
Personnel 12 0 
Abbreviations : see list of abbreviations p 4-5.  
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P. aeruginosa in home environment of CF and non-CF patients 
 
In contrast with the extensive studies on patient-to-patient transmission and on the presence 
of P. aeruginosa in the hospital environment, there are only a few reports on the prevalence 
of P. aeruginosa in the home environment of both CF and non-CF patients. These studies 
provide conflicting results. None of them studied the possibility of environment-to-patient 
transmission, neither did they compare genotypes of P. aeruginosa isolates recovered from 
either patients or from their home environment. The lack of knowledge about the exact role of 
the environment in the acquisition of P. aeruginosa by the CF patient is of concern to parents 
and physicians, and sometimes leads to questionable preventive measures, such as not 
drinking tap water unless it has been boiled or not visiting swimming pools (275, 276) and is 
also reflected in national guidelines with different policies regarding the preventive hygienic 
measures to be taken in daily life.  
   
Studies on prevalence of P. aeruginosa in both CF and non-CF houses 
 
Mortensen and colleagues (277) investigated 14 houses of CF patients colonized with B. 
cepacia complex  and 13 non-CF houses in the same geographical area. The P. aeruginosa 
colonization status of the CF patients was not reported. All houses harboured P. aeruginosa.  
Unfortunately, results were not reported separately for CF and non-CF houses.  
P. aeruginosa  was recovered from 26 out of 407 (6.4%) cultures taken in the homes.  The 
main source of P. aeruginosa  were drains: this pathogen was cultured from 10/106 (9.4%) 
samples of the drains of the kitchen sink and bathroom, shower heads and refrigerator drain 
pans. Other sources of P. aeruginosa were “personal items”  (5/130 (3.8%)  samples of 
clothes washer, soap, toothpaste, toothbrush) and vegetables (10/61 (16.4%) of the cultured 
vegetables).   
Regnath et al. (278) looked closely into the prevalence of P. aeruginosa in 102 households of 
118 CF patients. Cultures were taken of different aqueous sites in the homes and  
P. aeruginosa was detected in 71.4% of the CF houses. P. aeruginosa was mainly 
encountered in drains of bathroom and kitchen (40% of the shower drains, 35% of the 
bathroom and kitchen washbasin drains),  but also in 26.5% of the drainpipes of the toilet. 
Only 1.3% of the sponges, and  6.3% of the dish brushes harboured P. aeruginos.   
P. aeruginosa colonization status was known for 88 studied patients, of whom 28 were 
colonized.  In this study, the frequency and intensity of cleaning procedures did not have an 
impact on the detection rate of P. aeruginosa.  
In a Swiss study, Barben and colleagues (279) documented the presence of  P. aeruginosa 
in bathroom water of patients with cystic fibrosis. The prevalence of P. aeruginosa in 204 tap 
water specimens was low, with only two positive specimens of standing water, sampled 
during the summer. 
Studies on prevalence of P. aeruginosa in non-CF houses:  
Whitby et al. (280) examined 33 houses of hospital staff members and of people not working 
in hospitals. Of a total of 171 samples, only 9 P. aeruginosa posive cultures (5.3%)  from 4 
homes, two of which belonging to people working with P. aeruginosa, were detected. The 
vast majority of the positive samples (7 out of the 141 samples taken) was from the sink, 
bathroom and washbasin drains, and just one out of the 21 samples of taps. The remaining 
P. aeruginosa was detected in a soap dish (1/15), no P. aeruginosa was cultured from 21 
floor-cloths, dish-cloths, mops and sponges.  
Ojima (281) scrutinized 86 Japanese houses for the presence of different bacteria. In each 
house, cultures of 100 different sites were taken by direct agar contact plate method. P. 
aeruginosa was mainly found in sinks, dish washing tubs and drains in the kitchen 
(respectively  12.9, 19.6 and 27.1% of the cultures). Eighteen percent of the bathroom floors 
was contaminated with P. aeruginosa, and 6% of the wash pans and wash stools, nearly 
without contamination of the bathtubs. This was explained by the authors being the result of 
a different cultural-based use of the bathroom in  Japan, although this different use was not 
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specified. Ojima detected P. aeruginosa in 16% of the dish-washing sponges in the kitchen 
an 22% of the cleaning sponges in the bathroom.  
 
Conclusion: Studies on prevalence of P. aeruginosa in both CF and non CF houses indicate 
that drains in bathroom and kitchen are important reservoirs of P. aeruginosa. No 
comparison of contamination in CF versus non-CF houses has been made nor was possible 
transmission of  P. aeruginosa from the environment to the CF patient studied. This 
uncertainty on possible acquisition concerns CF patients and parents.  
 
Other potential environmental sources of P. aeruginosa mentioned in literature.  
Numerous other potential environmental sources of P. aeruginosa for CF patients have been 
discussed in literature. Acquisition through one of these sources however has never been 
proven.  
Dental units: In the early 1980s, a German study (282) identified P. aeruginosa in 74% of the 
water in dental chair units of private dental practices. Jensen and colleagues (283) reported 
contamination with P. aeruginosa in 18 out of 327 (5.5%) water samples from nine (11%) 
dental sessions. In one case, a genotypically identical P. aeruginosa strain was found both in 
water from the dental session and in the CF patient’s sputum. In a survey in  a dental 
hospital, 43% of the suction hoses were infected with P. aeruginosa and corroded at their 
attachment to the main dental chair unit. The problem was eliminated by replacement of the 
hose connectors (284).  
Whirlpools and hot tubs frequently harbour P. aeruginosa (285). In a study from Northern 
Ireland, 4/13 (30.8%) of hydrotherapy pools and 37/51 (72.5%) of jaccuzis/spas contained P. 
aeruginosa (286).  
Swimming pools, if correctly managed and disinfected by chlorine, are free of or contain very 
little P. aeruginosa. Standards however vary. In the study of Barben et al. (279) , none of the 
72 specimens from 28 outdoor pools in 2002 and  three specimens from 3 different paddling 
pools out of  46 pools (7%) in 2003 revealed P. aeruginosa. Both samples were from non-
public hydrotherapy pools. Moore et al. (286) detected P. aeruginosa in 26/68 (38.2%) of the 
swimming pools. Plastic animals used in swimming pools may be contaminated with P. 
aeruginosa and have been linked to an outbreak of folliculitis (287).  
P. aeruginosa is isolated from a number of plants and soil in the natural environment: it was 
detected in 24% of the soil samples but only in 0.13% of the vegetable samples from various 
agricultural areas of California (231). Ornamental potted plants can also harbour P. 
aeruginosa (288).  
Contamination of prepared vegetable salads with P. aeruginosa at home and in the hospital 
has also been described as a possible source of infection. Kominos et al. (289) detected P. 
aeruginosa from diverse fresh vegetables in the hospital kitchen. P. aeruginosa was also 
present on the hands of the kitchen personnel and on cutting boards and knives, suggesting 
acquisition of the organism through contact with the contaminated vegetables. Pyocine types 
of P. aeruginosa isolated from the clinical specimens were frequently identical to those 
recovered from vegetables. P. aeruginosa was recovered from 44% of the fresh vegetable 
salads from the hospital kitchen (290). Ingestion of P. aeruginosa-contaminated food  may 
lead to colonization of the oropharynx or colonization of the gastrointestinal tract . One study 
in CF patients however concluded that gastrointestinal colonization occurs as a result of 
respiratory infection and that the gut is not a significant reservoir of P. aeruginosa prior to 
pulmonary colonization as they detected a low percentage (<10%) of positive stool cultures 
for P. aeruginosa in CF patients not chronically colonized by this pathogen in contrast with 
positive stools in 8 of the 10 chronically colonized patients (291). 
The role of home nebulizers in transmitting potential pathogens has been studied. A 
significant proportion (25 to 55%) of the home nebulizers of CF patients are contaminated 
with P. aeruginosa (292-294).  When adequately disinfected and cleaned, nebulizers do not 
contain P. aeruginosa, as proved by Hutchinson et al. (295) and Reychler et al. (296). The 
latter assessed the in vitro effectiveness of 5 methods of disinfecting nebulizer equipment. 
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Following disinfecting procedures were studied: hypochlorite solution (0.02% active chlorine), 
acetic acid 3.5%, Hexanios 0.5%, washing-up detergent 0.5% and a dishwasher, tested with 
and without drying. One hundred sixty mouthpieces and 160 masks of nebulizers were 
artificially and massively contaminated with 16 strains of germs, including P.  aeruginosa. 
Acetic acid without drying was not effective to get completely rid of P. aeruginosa, and was 
not effective against S. aureus and B. cenocepacia.   
 
 
Routes of transmission: contact, droplet or airborne? 
 
Most patient-to-patient transmission of P. aeruginosa is thought to result from direct contact 
with infected secretions (e.g., during kissing), indirect contact with infected secretions (e.g., 
sharing a toothbrush, drinking from the same glass as another CF patient, or shaking hands 
with someone whose hands are contaminated with secretions), or via droplets (i.e., 
inspiration of large infectious particles that are spread by coughing, sneezing or singing and 
that can be inspired within a 1-meter distance from of an infected patient). Droplet 
transmission has been demonstrated by isolating P. aeruginosa from agar plates placed 0.5 
to 1 meter (242, 243), and even, though to a smaller degree, beyond the distance of one 
meter from a coughing CF patient (297).  
More recent studies also describe the possibility of airborne transmission  (i.e. inspiration of 
smaller infectious particles that remain suspended in shared air supplies that are transported 
over long distances via air currents). P. aeruginosa has been isolated out of the air 
surrounding P. aeruginosa colonized CF patients by using an air sampler (243, 253, 298) 
(299)  especially after coughing, performing lung function tests and physiotherapy.  Real 
airborne transmission however is difficult to prove and debated (300). 
While the routes of transmission are not fully understood, infected respiratory secretions may 
contaminate the health care environment, which then serves as a potential reservoir for P. 
aeruginosa. Contaminated hands of health care workers may further facilitate transmission. 
As P. aeruginosa is mainly found in sink drains, hand washing in contaminated sinks, 
generating aerosol of P. Aeruginosa, might be important in transmission of P. aeruginosa.  
 
General conclusion on environment-to-patient transmission in CF patients:  
 
The contamination with P. aeruginosa of CF health care settings and of the natural 
environment, including CF and non CF houses has been studied. Sometimes, P. aeruginosa 
strains matched patient’s strains, but it is unclear whether patients were the initial source of 
environmental contamination or whether the patient strains originated from the contaminated 
source. No studies conclusively demonstrate  that the environment is the major source for 
early infection. The uncertainty on possible acquisition of P. aeruginosa from the 
environment concerns both patient and physicians, and sometimes leads to questionable 
preventive measures.  
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P. aeruginosa in CF patients:  from initial infection to chronic colonization  
 
The first P. aeruginosa colonization episode can occur very early in the life of CF patients. 
After a first ever colonization episode by P. aeruginosa, patients may go through different 
episodes of colonization (intermittent colonization), preceding chronic colonization by months 
to years, eventually resulting in chronic infection (6, 49, 226). P. aeruginosa strains causing 
early infection usually have a nonmucoid phenotype, whereas P. aeruginosa strains in 
chronically colonized patients are mucoid and form biofilms. In this chapter the pathogenetic 
events associated with evolution from nonmucoid to mucoid  P. aeruginosa,  the course of P. 
aeruginosa infection in CF patients (from nonmucoid to mucoid P. aeruginosa , from initial 
colonization to chronic infection) and  the different and confusing definitions of P. aeruginosa 
colonization and infection in CF patients are discussed.  
 
Pathogenic events hypothesized to lead to chronic P. aeruginosa colonization.  
Once initial infection has occurred, P. aeruginosa in CF lungs sometimes survives despite 
both innate and acquired host defence strategies and  repeated courses of both systemic 
and inhaled antibiotics. To achieve this, P. aeruginosa has developed a huge 
armamentarium of immuno-evasive strategies including exoproducts, antibiotic resistance 
proteins and phenotypic changes that render them virtually unrecognisable from the initially 
colonizing P. aeruginosa.  P.  aeruginosa found in the CF lung are hypermutable (301). They 
possess the ability to react promptly to their environment not only by switching  genes on or 
off but also by an increased frequency of mutations.  
This hypermutability plays an important role in the change to the P. aeruginosa phenotype 
seen in chronically infected CF patients. This phenotype is characterized by slow growth, 
auxotrophy, alginate overproduction (mucoidity), antibiotic resistance and loss of motility 
(302-307).   
Exoproducts  
Pseudomonads produce a wide array of exoproducts, of which both elastase and alkaline 
protease protect against immune destruction by immunoglobulins, complement  and 
cytokines. Exotoxin A inhibits phagocytosis and suppresses the cell-mediated immune 
response. The siderophores produced by P. aeruginosa, such as pyocyanin, break down 
intercellular tight junctions, slow ciliary beat frequency  and thereby impair mucociliary 
clearance (176).  
Antibiotic resistance proteins  
P.  aeruginosa disposes of a wide variety of intrinsic antibiotic resistance mechanism such as 
the production of beta-lactamases, efflux pumps and a low permeability of the outer 
membrane. Moreover, P. aeruginosa has a remarkable ability to acquire further resistance 
mechanisms to multiple groups of antimicrobial agents, including beta-lactams, 
aminoglycosides and fluoroquinolones. Practically all known mechanisms of antimicrobial 
resistance can be observed: derepression of chromosomal AmpC cephalosporinase, 
production of plasmid or integron mediated beta-lactamases from different molecular classes 
(carbenicillinases, extended spectrum beta-lactamases , oxacillinases and carbapenem 
hydrolysing enzymes), diminished outer membrane permeability (through loss of OprD 
proteins), overexpression of active efflux systems with wide substrate profiles, synthesis of 
aminoglycoside modifying enzymes and structural alterations of topoisomerases II and IV 
determining quinolone resistance.  These mechanisms are often present simultaneously, 
thereby conferring multiresistant phenotypes (308).   
Phenotypic changes 
One of the mutation events in P. aeruginosa in chronically infected CF patients triggers 
conversion to a mucoid phenotype, which is almost pathognomonic for CF (309). In response 
to environmental triggers, such as nutritional stress and hypoxia found within a CF mucus 
plug, mutants are selected that overproduce mucoid exopolysaccharide (alginate), as 
represented in Figure 1 (190). This surrounds them, protecting them from adverse external 
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challenges, such as mucociliary clearance, the host immune response (non-oxidative killing 
by phagocytes) and antibiotics and is highly pro-inflammatory.  
 
 
Figure 1: Pathogenic events hypothesized to lead to chronic P. aeruginosa colonization 
(190)  
 
(A) In normal airway epithelia, the presence of a low-viscosity periciliary layer (PCL) of normal volume promotes 
efficient mucociliary clearance. A normal rate of epithelial cell oxygen consumption (QO2) results in no gradient in 
the partial pressure of oxygen (pO2) within the airway surface liquid (ASL). In the CF airway, (B) isotonic volume 
depletion of the PCL (denoted by downward arrows and bent cilia) results in reduced mucociliary transport 
(bidirectional horizontal arrow) and (C) persistent mucus hypersecretion (denoted by upward arrows from 
secretory gland/goblet cell units) with time increases the height of the luminal mucus layer/plugs. Elevated CF 
epithelial QO2 generates steep hypoxic gradients (dark colour in pO2 bar) in the thickened mucus layer. (D) P. 
aeruginosa bacteria deposited on mucus surfaces penetrate actively or passively (due to mucus turbulence) into 
hypoxic zones of the mucus masses. P. aeruginosa adapt within the hypoxic environment with increased alginate 
expression and the formation of microcolonies with potential evolution into biofilms. (E) Increased P. aeruginosa 
microcolony density and the presence of neutrophils render the mucus layer more hypoxic. P. aeruginosa 
microcolonies within the hypoxic mucus plugs resist host lung defenses, including neutrophils, and result in 
chronic airway infection (190).  
 
Another highly successful survival strategy involves the formation of biofilms. Singh et al. 
provided the first evidence that P. aeruginosa exists in biofilms within the CF lung (310). 
Initiation of biofilm formation is dependent on a process of quorum sensing (QS). QS allows 
bacteria to determine, by means of freely diffusible molecules such as acyl homoserin 
lactones (AHLs)  the presence of similar bacteria in the vicinity. Once these molecules reach 
a high concentration within the organism, genes controlling the formation of biofilm are 
expressed. In this state, microcolonies of bacteria are surrounded by a dense matrix, which 
protects against phagocytosis and prevents penetration by antibiotic agents. This phenotypic 
change is likely to play a major role in the persistence of P. aeruginosa infection in CF 
patients. The steps involved in biofilm formation are represented in Figure 2.  
 
 
 
45 
 
Figure 2: Steps thought to be involved in biofilm formation (177). 
 
The top row (A) diagrams what is believed to be occurring in the bottom row (B), which shows confocal 
microscopy of fluorescently labelled organisms. Single (planktonic) bacterial organisms are inhaled (I) and settle 
onto a surface such as the respiratory mucosa (II), where they multiply into microcolonies (III). These evolve into 
mushroom-like structures and a biofilm matrix (pink)is produced, which surrounds the by now large colonies of 
less metabolically active organisms (IV). On occasion, the biofilm matrix breaks down into parts and a shower of 
organisms leave the biofilm (V), which might cause respiratory exacerbation.  
 
Natural history of acquisition of P. aeruginosa and the evolution from non mucoid to 
mucoid P. aeruginosa infection in CF patients.  
 
Interesting data regarding the natural history of acquistion of P. aeruginosa and evolution 
from non mucoid to mucoid P. aeruginosa infection in CF patients come from follow-up of CF 
patients detected through neonatal screening projects: Li and co-workers (311) evaluated 
prospectively 56 CF patients, diagnosed through the Wisconsin CF Neonatal Screening 
Project. Patients were followed every 6 weeks during the first year of life and every 3 months 
thereafter from birth up to age 16 years. Cultures of respiratory secretions (sputum or 
oropharyngeal swabs) were taken every 6 months and in between if clinically indicated.  
Patients did not routinely receive anti–P. aeruginosa antibiotics after detection of P. 
aeruginosa, but could be started on at the discretion of treating physicians. A total of 1921 
cultures were collected with a mean interval of 4.04 months between cultures. Nearly one 
third (29%) of the patients acquired nonmucoid P. aeruginosa already in the first 6 months of 
life. Nonmucoid P. aeruginosa was acquired at a median age of 1 year (95% CI 0.6- 1.5 
years), mucoid P. aeruginosa was detected at a median age of 13 years (95% CI, 10-14.9 y). 
All patients acquired P. aeruginosa reaching 13 years. The age-specific prevalence of 
nonmucoid P. aeruginosa increased from birth to age 4 years (86%); of mucoid  
P. aeruginosa from age 4 years (4%) to 16 years, when 92% of the 13 patients reaching that 
age developed mucoid P. aeruginosa. All patients who developed mucoid P. aeruginosa had 
acquired nonmucoid P. aeruginosa first. In contrast with the short transition time from no  
P. aeruginosa to nonmucoid P. aeruginosa, the transition time from nonmucoid to mucoid  
P. aeruginosa was relatively long (median 6.10 years  (95% CI 4.47- 8.21y)).  
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Data on the early first acquisition of P. aeruginosa in CF patients were confirmed by other 
investigators. Burns et al. (49) investigated P. aeruginosa from oropharynx (OP) and 
bronchoalveolar lavage fluid (BALF) in a cohort of 40 CF patients during the first 3 years of 
life. Bronchoscopy with BAL was performed annually. OP cultures were taken at 3-month 
intervals, until the third bronchoscopy. In 72.5% of patients, P. aeruginosa could be 
demonstrated in BALF and/or OP cultures during their first 3 years of life.  
Whereas in the data of Li et al. (311), all patients acquired nonmucoid P. aeruginosa before 
conversion to mucoid P. aeruginosa, other studies on acquisition of P. aeruginosa in birth 
cohorts detected by newborn screening (312, 313) report mucoid P. aeruginosa at detection 
in a substantial proportion of the patients. In the study of Nixon et al. (312), more than half of 
the patients (13 out of 24) had mucoid P. aeruginosa at detection. P. aeruginosa was mucoid 
at detection in 6 out of the 33 CF patients in the data of Douglas et al. (313). It is however 
worth noting that in both studies detection of P. aeruginosa was done only by yearly culture 
of BALF, and that no OP or sputum cultures were performed in between.  The authors 
explain the observation of high prevalence of the mucoid phenotype by the possible delay in 
detection of P. aeruginosa, due to taking samples only annually. However, the possibility of 
acquisition of mucoid P. aeruginosa right from the start through patient-to-patient spread 
cannot be excluded.  
 
Studies on the natural evolution from first isolation to chronic colonization by  P. aeruginosa 
Without antibiotic treatment, the natural history of P. aeruginosa infection in CF is often 
towards a rapid development of chronic colonization by P. aeruginosa. Johansen et al. (314) 
reviewed the Danish data (1965-1990) from intermittent and chronic P. aeruginosa infection. 
During the study period, 239 patients had intermittent episodes of P. aeruginosa colonization 
and 182 patients became chronically infected, all having been intermittently colonized 
previously. The median time interval before patients became chronically infected was 12 
months (range 0-69 months). In 33 of 182 patients with chronic infection the initial episode of 
P. aeruginosa colonization developed immediately into chronic infection; the remaining 149 
patients first became P. aeruginosa -free for a varying period of time before ultimately 
developing chronic infection. The mean age of patients acquiring chronic infection with P. 
aeruginosa was 9.7 years.  Kerem et al. (315) reported that 199 out of 309 (69%) CF patients 
had more than 50% P. aeruginosa positive cultures over the two years following  initial 
colonization; indicating chronic colonization.  
 
Definitions of (chronic) colonization and infection by P. aeruginosa 
Unfortunately, comparison of the different studies on chronic colonization by P. aeruginosa is 
hampered by the lack of agreement in the definitions of chronic colonization/infection. 
Currently, there is no universally accepted definition for chronic P. aeruginosa 
colonization/infection. An overview of the different criteria is presented in Table 3.  Most 
European CF centers use the “European consensus criteria” agreed by Döring et al. (316) or 
the “Leeds criteria” defined by Lee et al. (317). In this thesis, “colonization” and “infection” are 
used respecting the definitions used by the different authors.  
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Table 3: overview of the different definitions of (chronic) P. aeruginosa colonization/infection.  
 
European consensus criteria (316) 
• Lung colonization by P. aeruginosa: “Presence of P. aeruginosa in the bronchial 
tree without direct (inflammation, fever, etc.) or indirect (specific antibody response) 
signs of infection and tissue damage” 
• Chronic lung colonization by P. aeruginosa: “Presence of P. aeruginosa in the 
bronchial tree for at least 6 months, based on at least three positive cultures with at 
least one month intervals between them without direct (inflammation, fever, etc.) or 
indirect (specific antibody response) signs of infection and tissue damage”. 
• Lung infection by P. aeruginosa: “Presence of P. aeruginosa in the bronchial tree 
with direct (inflammation, fever, etc.) or indirect (specific antibody response) signs 
of infection and tissue damage. Infection can also be diagnosed on the basis of a 
positive antibody response in at least two examinations for patients who do not 
expectorate and present with negative bacterial cultures” 
• Chronic lung infection by P. aeruginosa: “Presence of P.  aeruginosa in the 
bronchial tree for at least 6 months, based on at least three positive cultures with at 
least one month intervals between them with direct (inflammation, fever, etc.) or 
indirect (specific antibody response) signs of infection and tissue damage. Chronic 
infection can also be diagnosed on the basis of a positive antibody response in at 
least two examinations for patients who do not expectorate and present with 
negative bacterial cultures.”  
 
The Leeds criteria (317) classify CF patients as:  
• Never infected by P. aeruginosa: P. aeruginosa has never been cultured from 
sputum or cough swab. 
• Free of P. aeruginosa infection: no growth of P.  aeruginosa during the previous 12 
months, having previously been P.  aeruginosa culture positive. 
• Intermittently infected by P. aeruginosa: when ≤ 50% of months, when samples had 
been taken, P.  aeruginosa cultures are positive.  
• Chronically infected by P. aeruginosa: when >  50% of months when samples had 
been taken, P.  aeruginosa cultures are positive. 
 
The Cystic Fibrosis Trust in the UK uses in the consensus guideline “Suggestions for 
prevention and infection control” (318) the definition proposed by Brett et al. (319) defining 
chronic infection with P. aeruginosa as “the regular culture of P. aeruginosa from the sputum 
or respiratory secretions, on two or more occasions, extending over 6 months or a shorter 
period if accompanied by a sustained rise of anti-Pseudomonas antibodies”, although they 
also mention the Leeds criteria in this consensus guideline.  
 
In Denmark, following definitions are used, known as the “Copenhagen criteria” (247):   
• Chronic P. aeruginosa infection: “Persistent presence of P. aeruginosa for at least 6 
consecutive months, or less when combined with the presence of two or more P. 
aeruginosa precipitins”.  
• Intermittent P. aeruginosa colonization: “Culture of P. aeruginosa at least once and 
the presence of normal levels of precipitating antibodies against P. aeruginosa’”. 
 
According to Ballmann et al. (320) and Kerem et al. (315) a patient is considered chronically 
infected by P. aeruginosa when having more than 50% of cough swabs or sputum samples 
positive in a 12-month period. Fitzsimmons et al. (321) classified a patient as chronically 
infected if the last sputum sample of each year grows P. aeruginosa.   
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Each definition holds its advantages and drawbacks.  
The definitions proposed by Brett (319), Ballman (320), Kerem (315) and Fitzsimmons (321) 
are vague and do not offer any advantage in practical organisation of patient care.  
The European consensus criteria (316) are clinically relevant, allowing an easy tool for 
categorizing CF patients according to P. aeruginosa colonization status. By also 
implementing the results of P. aeruginosa antibodies, they overcome the problem of difficult–
to-classify patients, e.g. those with intermittently positive P. aeruginosa cultures. The 
difference between infection and chronic infection however is not clear as there is an overlap 
in definition, both mentioning “Infection can also be diagnosed on the basis of a positive 
antibody response in at least two examinations for patients who do not expectorate and 
present with negative bacterial cultures”. Furthermore, P. aeruginosa serology tests are not 
widely available.   
This also holds true for the “Copenhagen” definition of intermittent colonization and chronic 
infection (247), although it offers a precise classification tool but is very laborious, needing 
monthly respiratory cultures.  
The Leeds criteria (317) exclusively rely on culture methods, in contrast with the Danish and 
European consensus criteria, and give a detailed classification of CF patients according to  
P. aeruginosa status.  The major drawback of the these criteria is  that it is very laborious to 
set up segregation for the different cohorts.  The Leeds criteria are the best documented and 
show good agreement with clinical parameters of the CF patients. In the initial report of Lee 
et al. (317) the‘ chronic’ group had significantly worse chest X-ray scores, and lower FEV1 
values than the ‘free’ or ‘never’ categories (p<0.004). The ‘intermittent’ group had 
significantly higher chest X-ray scores than the ‘chronic’ group (p<0.0001), and a significantly 
lower % predicted FEV1 value than the ‘free’ or ‘never’ groups (p<0.0003). ‘Chronic’ patients 
were associated with a positive, and ‘never’ patients with a negative P. aeruginosa antibody 
result (p<0.001). These criteria proved also to be relevant for predicting future infection 
status: 88% of the ‘chronic’ patients remained in this category five years later. Patients 
defined as ‘intermittent’ were most likely to remain in this category when reassessed 5 years 
later, but with 15% of the ‘intermittent” reverting to ‘free’  and 15% progressing to ‘chronic’. 
The value of the Leeds criteria for P. aeruginosa infection was later on confirmed by 
Proesmans et al. (322). They evaluated the use of this definition in 193 CF patients, using 
clinical, immunological and lung function parameters and confirmed the agreement between 
P. aeruginosa status, the clinical status and level of P. aeruginosa antibodies. Disease 
markers, such as FVC,FEV1 and weight for height were significantly worse in the chronic 
group. P. aeruginosa antibodies differed between the groups and were very high and 
statistically significant different from all other groups in the ‘chronic’ group and very low in the 
‘never infected’ group en control group.  
 
Conclusion: Studies demonstrate that the first P. aeruginosa infection occurs early in life. 
The time span from first isolation of P. aeruginosa to chronic colonization is variable and 
dependent on several factors, such as patient segregation and early treatment regimens, but 
also on definitions of chronic colonization used. The role of segregation and early treatment 
in the delay of chronic  P. aeruginosa colonization is discussed in Chapter II.  
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Clinical impact of P. aeruginosa infection in CF patients  
 
Plenty of reports extend on the deleterious effect of P. aeruginosa in CF patients. The 
presence of P. aeruginosa in respiratory cultures is associated with lower survival rates (312, 
323-326), lower pulmonary function tests (312, 315, 325-328), more respiratory symptoms 
(39), worse chest X-ray scores (39, 210, 325, 326, 328) and worse clinical parameters (210, 
312). Acquisition of mucoid P. aeruginosa was associated with an accelerated rate of decline 
in pulmonary function (326). Emerson et al. (329) analyzed prognostic indicators of 8-year 
mortality and morbidity in patients ages 1–5 years from the 1990 US Cystic Fibrosis 
Foundation Patient Registry. The 8-year risk of death was 2.6 times higher in patients who 
had respiratory cultures positive for P. aeruginosa in 1990 than in children without P. 
aeruginosa. Children from whom P. aeruginosa was isolated in 1990 had higher rates of 
continued infection in 1998, more frequent hospitalizations for acute respiratory 
exacerbations, lower percent predicted FEV1 values, and lower weight percentiles. 
 
Conclusion : P. aeruginosa infection is clearly associated with poorer clinical outcome in CF 
patients.  
 
 
 
Eradication therapy for P. aeruginosa colonization episodes in CF patients not 
chronically colonized by P. aeruginosa 
 
P. aeruginosa strains causing early infection usually are antibiotic sensitive and of low 
bacterial density in the airways (49, 226). Aggressive treatment of these early infecting 
strains often successfully eradicates P. aeruginosa. Chronic P. aeruginosa  infection is 
clearly associated with poorer clinical outcomes among CF patients. As a result, the 
treatment strategy has shifted from suppressive therapy in patients chronically colonized by 
P. aeruginosa to attempts at early eradication therapy as soon as P. aeruginosa is detected 
(330, 331).  
 
Historical overview of early eradication treatment 
The initial observations of the favourable effect of eradication treatment for early                  
P. aeruginosa isolates dates back to the eighties and early nineties.  
Littlewood et al. (332) observed that treatment with inhaled colomycin in 7 patients with 
recent P. aeruginos acquisition resulted in a significant reduction of P. aeruginosa positive 
cultures.  
Steinkamp et al. (333) treated 28 CF children with recent colonization with iv anti-
pseudomonas antibiotics (azlocillin + tobramycin) during 2 weeks. Eighteen (64%) of these 
were free of P. aeruginosa at the end of the treatment. This number gradually declined over 
time, leaving  just 1 patient  (3.5%) free of P. aeruginosa after 15 months. This high number 
of recurrence might be explained by the long time lapse between detection of the first 
positive P. aeruginosa respiratory culture and the start of IV treatment (1-11months, median 
5 months).  
Valerius et al. (334) compared treatment with oral ciprofloxacin and inhaled colomycin for 3 
weeks with placebo for 3 weeks in 26 CF patients with a new P. aeruginosa episode. At the 
end of the 27 months observation period, the treatment group had significantly less  
P. aeruginosa positive cultures and a significantly lower rate of chronic infection.  
 
Eradication trials  
As a result of these early observations, several eradication studies were undertaken, both 
randomized controlled trials (RCT)  and cohort studies. The different eradication trials are 
summarized in Table 4 (see attachment). Comparison between the different studies however 
is difficult because of different methodologies, different eradication treatment regimens, 
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different outcome measures and different definitions of eradication and chronic colonization 
and/or chronic infection (see Chapter II). Below we will use both terms (colonization/infection) 
equivalently. 
 
• Studies on delay in chronic infection  
The Danish group published extensively on their long-lasting experience with eradication 
treatment. Details on the eradication treatment given in the studies can be consulted in Table 
4. In the absence of treatment for initial P. aeruginosa colonization and of segregation 
measures, approximately 10% of the CF patients will become chronically infected directly 
after the first positive culture. The remainder develops chronic infection after a median time 
of 12 months (314). Valerius et al. (334) observed that a significantly lower number of the 
treated patients evolved into chronic infection after 27 months compared to the placebo 
group (14% versus 58%). The experience continued and Frederiksen et al. (335) reported 
that only 16% of the treated patients developed chronic infection after 3.5 years compared to 
72% of the historic control patients. The “Early aggressive eradication therapy for intermittent 
P. aeruginosa airway colonization in CF patients: 15 years experience” was published in 
2008 (336). Of the 99 patients with a first ever P. aeruginosa isolate in the study, 12 patients 
developed chronic infection after a median time of 3.7 years after the first ever isolate (0.5-
10.3 y). A Kaplan Meyer estimate showed that up to 80% of the patients were protected 
against development of chronic infection for up to 15 years. Patients developing chronic 
infection had a significantly shorter P. aeruginosa free time interval after treatment of the first 
isolate compared to patients remaining intermittently colonized. Treatment failure, defined as 
a P. aeruginosa positive culture immediately after ended treatment of the first ever  
P. aeruginosa colonizaton episode, was a strong risk factor for development of chronic 
infection after 3 to 4 years (OR 5.8).  
 
• Studies on microbiological effect: eradication, recurrence of P. aeruginosa and time 
to recurrence  
These studies on the microbiological effect of eradication treatment are difficult to compare 
because definitions of eradication and/or P. aeruginosa free time period differ between 
studies.   
Eradication is in some studies defined as “three negative respiratory culture results within 6 
months of treatment” (337, 338); some studies also include negative P. aeruginosa 
antibodies in their definition of eradication (339, 340). Other investigators delineate 
successful eradication as negative P. aeruginosa culture at the end of the eradication 
treatment (336, 341) or at various time points after the end of treatment (113, 333, 342, 343). 
Still others use different definitions (312, 344, 345) or in some studies, eradication is not 
defined (346).  
The P. aeruginosa free time period includes in some trials the treatment period (344, 345), 
other start counting from the end of the treatment onwards. In some studies, the treatment 
group taken as a whole (336, 337) and in others the P. aeruginosa free time period is 
calculated only for those who have a recurrence of P. aeruginosa (347). In other trials, the  
P. aeruginosa free time period is calculated but not defined (346). 
Different treatment regimens have been studied. The majority of the studies uses inhaled 
antibitiocs (mainly tobramycin) or the combination of oral ciprofloxacin and inhaled antibiotics 
(tobramycin or colomycin) for varying lengths of time. All studies are outlined in Table 4. 
Whatever early eradication treatment is used, all trials report successful eradication and/or 
significantly less positive P. aeruginosa cultures during treatment (332, 334, 348). The more 
recent eradication trials (2000-2010) also report the percentages of eradication immediately 
after or within 6 months after treatment , these vary between 80 and 100% (113, 337, 338, 
342-346, 349).  
Data on the recurrence of P. aeruginosa are extremely diverse, with percentages of 
recurrence varying between 12% (343) and 100% (346). Recurrence rate estimates are 
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influenced by the follow up time of the study: it is logical that chances of recurrence increase 
with lengthened observation periods. 
Munck et al. (346) reported a new P. aeruginosa episode in all patients after a median time 
of 18 months, Tacetti et al. (337) in 51% of the treated patients after a median time of 18 
months. In the Elite trial (347), the median time to recurrence of P. aeruginosa was 26 
months for patients in the 28 day treatment group and 25.8 months for the patients in the 56 
day treatment group (ns). Thalhammer and Eber et al. (344, 345) notified a 29% recurrence 
after median time period of 8 months, but in this study the time while still on inhaled 
antibiotics was included in the calculation of the P. aeruginosa free time period. 
Unfortunately, no follow-up data are provided for the studies of Thalhammer and Eber et al. 
(344, 345) and Tacetti et al. (337). The results of Douglas et al. (313) suggest an extremely 
low percentage (12%) of  P. aeruginosa recurrence. This can be explained by the use of only 
annual BAL cultures to detect P. aeruginosa, without culture of other respiratory samples in 
between. The P. aeruginosa free time period in “the 15 year Danish experience” (336) was 
significantly less in non-treated versus treated patients, with a (statistically not significant) 
trend to longer P. aeruginosa free time periods in the 3 month regimen (10.4 m of  
P. aeruginosa free time) compared to the 3 week treatment regimen (5 months) and the 
nontreated group (1.9 months). The less successful results of eradication of Steinkamp et al. 
(333) and Nixon et al. (312) can presumably be explained by late diagnosis (annual BAL for 
detection, also indicated by the high number of mucoid P. aeruginosa at detection in the 
study of Nixon) and by late start of IV treatment after detection of P. aeruginosa  (1-11 
months, median time 5 months) in the study of Steinkamp et al..  
 
• Studies on effect of eradication treatment on clinical parameters  
Effect on clinical data seems harder to prove.  
Frederiksen et al. (335) demonstrated a favourable effect of the early treatment on lung 
function parameters.  Pulmonary function was maintained or increased during the year after 
treatment in comparison with the control group, in which pulmonary function declined  
(p < 0.01). Although some of the treated patients developed chronic P. aeruginosa infection, 
these had significantly better pulmonary function at the onset of chronic P. aeruginosa 
infection compared to the control patients (p < 0.001). Frederiksen et al. used a historic 
control group, but apart from the intensive antibiotic protocol, all other aspects of infection 
control and treatment were the same for the study group and the historic control group.  
Other trials investigating the effect of early eradication on pulmonary function (112, 333, 340, 
347) failed to detect a favourable influence. Unfortunately, these studies have a short 
duration of follow-up (12 to 27m).   
Steinkamp et al. (111, 333) reported a significantly better weight gain immediately after 
intravenous antibiotic treatment.  
Taking into account however the deleterious effect of chronic P. aeruginosa on the clinical 
outcome, it seems logical that preventing or delaying chronic infection should have an 
advantageous effect on clinical parameters. Effect on clinical data however is currently 
scarce, this may be due to the short observation time in most studies.  
 
• Head-to-head comparison of different treatment regimens  
As result of these observations and trials, the use of eradication treatment for P. aeruginosa 
in patients not chronically colonized/infected by P. aeruginosa has become the mainstay of 
treatment. The optimal route of delivery of anti-P. aeruginosa  antibiotics (IV/oral/inhalation or 
combination) nor the optimal duration of eradication treatment for long lasting eradication 
(and also minimizing the risk of side-effects) is currently unknown.  
To the best of my knowledge, up till now, only 5 studies compared different treatment 
strategies. Three of these have been presented at the NACFC 2009, detailed results haven’t 
been published yet.  
The “Danish experience” learned that the 3 month eradication regimen with oral ciprofloxacin 
and inhaled colistin tends to be superior than the 3 week regimen. This observation led to a 
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change in early treatment policy to a 3 month regimen from the first P. aeruginosa culture on 
(336).  
The Early Pseudomonas Infection Control (EPIC) (350) program consists of a randomized 
multicenter trial in 304 CF patients  ages 1–12 years at first isolation of P. aeruginosa from a 
respiratory culture. Trial participants are assigned for 18 months to either anti-pseudomonal 
treatment on a scheduled quarterly basis (cycled therapy) or based on recovery of P.  
aeruginosa from quarterly respiratory cultures (culture-based therapy). The study drugs 
include inhaled tobramycin (300 mg bid) for 28 days, combined with either oral ciprofloxacin 
(15–20 mg/kg bid) or oral placebo for 14 days. The primary endpoints of the trial are the time 
to pulmonary exacerbation requiring IV antibiotics or hospitalization for respiratory 
symptoms, and the proportion of patients with new P. aeruginosa -positive respiratory 
cultures during the study. Eradication was achieved in > 82% of patients receiving inhaled 
tobramycin 300mg bid ± oral ciprofloxacin. There was no significant difference in endpoints 
between culture-based therapy and prophylaxis (cycled therapy) and no significant difference 
in endpoints with the addition of oral ciprofloxacin to inhaled tobramycin versus inhaled 
tobramycin monotherapy.  
A prospective study in Belgium (349) randomized 50 CF children at first isolation of  
P. aeruginosa to inhaled tobramycin 300 mg bid for 28 days, or inhaled colistin 2 MU bid plus 
oral ciprofloxacin 10 mg/kg tid for 3 months. According to the interim analysis of 32 patients, 
eradication was achieved in 14 of 17 tobramycin-treated patients (82.4%) compared to 14 of 
15 patients treated with the colistin/ciprofloxacin combination (93.3%). The difference in 
outcomes between the 1-month and 3-month treatment regimens was statistically not 
significant (p=0.14).  
A comparative trial of tobramin 300mg/ciprofloxacin and colistin/ciprofloxacin for 28d in 136 
CF children (338) reported no difference in the rate of eradication with the two regimens. 
Although these studies were not able to detect a superior regimen, inclusion of more patients 
and a longer follow-up period might help to reveal differences.  
Keeping this in mind and having a critical look at the study design of the EPIC trial, one can 
suggest that a 2 week duration of oral ciprofloxacin might be too short to detect any 
differences in eradication. In the study of Tacetti and colleagues (338) the difference 
between inhaled tobramycin and colomycin might be too small to detect differences in 
treatment outcomes. From that point of view, the study of Proesmans and colleagues (349) is 
very interesting of design, comparing two widely used but totally different eradication 
schedules (inhaled tobramycin 300mg bid versus oral ciprofloxacin and inhaled colomycin for 
3 months), although the study group of this trial might be too small to detect any differences 
in outcome.  
Conclusion: Head-to-head comparison of different treatment regimens has until now not 
defined a superior treatment regimen.  
 
• Can the acquisition of P. aeruginosa be prevented by antibiotic therapy?  
This question remains unanswered till now, as few studies addressed this topic. Long term 
antibiotics are always used with caution because of fear for side effects and development of 
antibiotic resistance.  
Heinzl and colleagues (351) reviewed 14 year data on the effect of nebulized gentamicin bid 
in “high risk “ patients on long term treatment and compared these with high risk patients who 
stopped the treatment prematurely. No one of the 12 patients on long term treatment (mean 
treatment duration 77 months, range 26-416 months) acquired P. aeruginosa during the 
study period, compared to 7 out of 16 patients who stopped treatment prematurely (mean 
treatment duration 41.8 months, range 3-106 months).  
In the 18 months EPIC trial, as mentioned above, there was no significant difference on 
endpoints between culture-based therapy and prophylactic cycled therapy (350). It must be 
noted that patients entered this study after a first ever P. aeruginosa colonization episode 
and consequently were not  P. aeruginosa-naïve.  
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Tramper-Stranders et al. (352) studied the value of prophylactic antibiotic therapy in 65 
children with CF without P. aeruginosa. In this 3 year triple-blind RCT, patients were treated 
3 monthly with a 3 week course of oral ciprofloxacin (10mg/kg bid) and inhaled colistin (1MU 
bid) or placebo. There was no difference in acquisition of P aeruginosa infection between the 
control and treatment groups (annual incidence 14% vs 11%). Chronic infection was 
observed in 19% of the control patients and 12% of the treated patients. 
Conclusion: Up until now, no studies have demonstrated the favourable effect of 
prophylactic antibiotic treatment in prevention of infection with P. aeruginosa.  
 
• Does early eradication treatment result in eradication or suppression of P. 
aeruginosa? 
So far, it is clear that early eradication treatment reduces the number of positive                   
P. aeruginosa cultures, extends the P. aeruginosa free time period and delays the onset of 
chronic infection. However, the main question whether the initial P. aeruginosa is really 
eradicated after a treatment or whether the eradication treatment only results in temporary 
reduction of the bacterial load escaping the sensitivity of the detection techniques used 
(culture, PCR), is not yet touched upon. An alternative explanation of the finding of an 
identical P. aeruginosa genotype at follow-up samples might be reinfection from the same 
initial source. This question on eradication versus suppression can be boarded by studying 
the initial P. aeruginosa genotypes and comparing them with the genotypes of subsequent P. 
aeruginosa isolates. This difference might be very important in the evaluation of the efficacy 
of eradication treatment. Genotyping of P. aeruginosa isolates was previously applied in 
epidemiological studies of P. aeruginosa in chronically colonized CF patients (255, 260, 353) 
but longitudinal data on the genotype of P. aeruginosa isolates after initial colonization and 
eradication treatment are limited:  
In the study of Munck et al. (346) 14 patients (74%) were colonized by a P. aeruginosa strain 
with a genotypic profile different from that of the first isolate and the other 5 patients had 
subsequent P. aeruginosa isolates with identical genotypes. No difference between both 
groups in terms of mean interval between first and second P. aeruginosa isolations was 
found.  
Taccetti et al. (337) reported data on genotyping for 16 patients with at least one subsequent 
P. aeruginosa isolate and found that acquisition of P. aeruginosa isolates with a different 
genotype occurred in 73% of the 50 episodes. These data were not presented in relation with 
subsequent chronic colonization status.  
Whereas these studies suggest that a minority of the P. aeruginosa recurrences are regrowth  
of a partially suppressed P. aeruginosa strain, others investigators revealed the opposite: 
Gibson (342) examined P. aeruginosa genotypes of BAL and OP cultures  in those patients 
with 2 or more P. aeruginosa positive cultures during the study. In the 6 patients with failed 
eradication (defined as a positive culture for P. aeruginosa in follow-up BAL), genotype of P. 
aeruginosa in both BAL samples (baseline and follow-up) were identical. Six out of 24 
patients (25%) who initially cleared the infection but later on had a new positive OP culture, 
had a different follow-up P. aeruginosa genotype compared with the  baseline BAL or OP 
culture.  
In the ELITE trial (347), 12 out of 21 patients (57%) had the same P. aeruginosa genotype at 
follow-up cultures.  
Conlusion: Comparison of genotypes of P. aeruginosa in initial and subsequent P. 
aeruginosa  isolates give a clue as to whether eradication treatment really was succesfull. 
The currently available data vary; with as many as 25% to 80% of identical P. aeruginosa 
genotypes at follow-up samples, indicating eradication failure or reinfection from the same 
initial source.  Ideally, every study on eradication treatment and those comparing treatment 
regimens should include genotypic characterization of P. aeruginosa.     
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• Is eradication of mucoid P. aeruginosa strains possible?  
It is often stated that mucoid strains of P. aeruginosa cannot be eliminated from the lower 
airways, but recent studies have suggested that eradication of these mucoid strains can be 
achieved with early, aggressive therapy. Gibson et al. (113) have reported eradication of 
mucoid and nonmucoid P. aeruginosa with inhaled tobramyin 300mg.  A recent study in the 
UK (354) indicates that eradication of mucoid P. aeruginosa is a realistic clinical goal. A 
retrospective chart review of pediatric patients seen at one centre in the period 1999-2008 
identified 116 subjects with at least one episode of mucoid P. aeruginosa infection and at 
least one year of follow-up. A total of 67 of 116 patients (57.8%) cleared mucoid P. 
aeruginosa for more than 1 year; 38 of these 67 patients (32.8% of the total group) remained 
P. aeruginosa free for a median time of 55 months (range 12-103 months) and a median 
number of 30 clear cultures (range 2-106  cultures). Unfortunately, no information is given on 
the eradication treatments used.   
Conclusion: Recent data indicate that eradication of mucoid P. aeruginosa is possible.  
 
 
General conclusions on eradication treatment for P. aeruginosa in patients not 
chronically colonized by this pathogen. 
The different studies on eradication treatment all agree on the favourable effect of antibiotics 
on eradication of P. aeruginosa, on the frequency of detection of P. aeruginosa and on the 
delay in onset of chronic P. aeruginosa infection. Early treatment for P. aeruginosa 
colonization/infection episodes is now considered the standard of care in the CF centres. 
More studies however are needed to determine the optimal treatment regimen and duration 
of eradication treatment. Ideally, every study on eradication treatment and those comparing 
treatment regimens should include genotypic characterization of P. aeruginosa.     
 
Early diagnosis of P. aeruginosa infection  
INTERMEZZO: Phenotypic versus molecular/genotypic methods for detection and 
typing of Pseudomonas aeruginosa  
 
• Detection of Pseudomonas aeruginosa 
Methods used for the detection of P. aeruginosa can be divided into phenotypic and 
genotypic procedures. Phenotypic procedures take advantage of biochemical, physiological 
and morphological phenomena such as cell and colony morphology, cell wall staining 
properties and the ability of a microbial species to grow under a given set of environmental 
conditions (e.g. temperature, oxygen dependency, osmolarity and the need for certain 
nutrients).  
P. aeruginosa, a gram negative rod, has some typical morphologic and biochemical 
characteristics, allowing identification when cultured on solid media. P. aeruginosa produces 
pigments (pyoverdin and pyocyanin), resulting in typical green to green-blue colonies on 
culture media.  However, morphologically, P. aeruginosa colonies are very diverse, 
especially for strains isolated from CF patients. Environmental strains, in contrast with 
chronic infecting strains, are often flat with a metallic sheen and may have a gelatinous or 
slimy appearance, particular in areas of heavy growth. Other colonial variants include the 
small colony variants and the mucoid morphotypes, the latter often seen in CF patients 
chronically colonized by P. aeruginosa. P. aeruginosa is able to grow on a wide variety of 
media and can metabolize a large array of carbon sources: it produces acid from sugars 
such as glucose, fructose and xylose, but not lactose and sucrose. P. aeruginosa is strongly 
oxidase positive and can grow at 42°C.  Commonly used sel ective media are cetrimide agar 
and MacConkey agar, which inhibit the growth of many other organisms. The Laboratory 
Bacteriology Research (LBR) of our research group compared the sensitivity for detection of 
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P. aeruginosa of different culture media and found no difference between McConkey agar, 
Cetrimide agar and Cetrimide broth  
In the case of CF respiratory samples, most routine laboratories use culture techniques to 
detect bacterial species in the respiratory samples. However, it has been shown that 
conventional culture methods of sputa from CF patients frequently fail to identify the 
pathogens, which were shown to be present by means of PCR (355). Misidentification by 
culture can occur due to the P. aeruginosa phenotypic variants seen in chronically colonized 
CF patients such as the pyoverdine negative mutants, the slowly growing variants, the small 
colony variants and the auxotrophs, which do not grow on standard media (356). For the 
molecular detection of Pseudomonas species, several assays have been described  (355, 
357-365). Comparison of conventional culture methods and PCR for detection of P. 
aeruginosa are discussed later on this chapter. A brief explanation of the PCR technique is 
given here. PCR is a technique which can generate, in just a few hours, thousands to 
millions copies of a particular piece of DNA, starting from a single piece of DNA or a few 
copies. Amplified DNA can subsequently be visualized by gel electrophoresis. Using this 
technique, the negatively charged DNA fragments migrate toward the positive electrode 
through a prepared agarose gel. After electrophoresis and addition of an ethidium bromide 
stain, which forms a complex with nucleic acids, exposure of the gel to ultraviolet light 
demonstrates the amplified fragment as a single fluorescent band. Advantages of the PCR 
technique are rapidity, good sensitivity and specificity. However, real-time PCR reduces the 
work-load and the time-to-result, because no gel electrophoresis is needed, and moreover 
and most importantly, because it enables the quantification of targets (e.g. P. aeruginosa 
cells) present in the sample. Real-time PCR is a method in which the accumulation of PCR 
products over time is measured directly, by means of a fluorescent signal, increasing 
proportionally to the amount of generated PCR product. Using an external standard, of which 
the DNA concentration is known, the concentration of DNA in the unknown sample can be 
quantified. Several real-time PCR-formats (SYBR Green, hydrolysis probe, hybridization 
probes) are already developed. In 2009, the LBR at the Ghent University Hospital compared 
the sensitivity of conventional PCR, combined with two different detection methods, with the 
sensitivity of four real-time PCR-formats for the detection of P. aeruginosa in sputum and 
concluded that the probe based real-time PCR-formats allowed for the most sensitive 
detection of P. aeruginosa in sputum (366).    
 
• Typing of Pseudomonas aeruginosa 
Until the early nineties, typing of P. aeruginosa for epidemiologic purposes relied on bacterial 
phenotypic characteristics, such as serospecificity of lipopolysaccharides (LPS), 
susceptibility to bacteriophages, bacteriocin production and antibiotic susceptibility. Although 
effective in certain clinical settings, some of these methods have been found to be 
inadequate under conditions in which P. aeruginosa undergoes phenotypic conversion. 
Moreover, P. aeruginosa strains of CF patients are frequently endowed with rough LPS, 
which renders them refractory to typing with systems that rely on agglutination with antisera 
or on phage susceptibility. Therefore, genotyic procedures were further developed. The 
starting point of these analyses is that the genome of each individual (and also each germ) is 
unique. A multicentre comparison of methods for typing strains of CF patients showed that 
the chromosomal DNA restriction fragment length polymorphism analysis (RFLP) had the 
greatest discriminatory power, in comparison with 10 phenotypic techniques (367). The major 
drawbacks of these restriction digestion based genotypic typing techniques are the need for 
a high degree of technical skills, and for a large quantity of high-quality DNA or RNA. 
Therefore enzymatic amplification of nucleic acid sequences has been increasingly applied 
for genotyping.  
PCR has been extensively evaluated for genotyping (368). This technique has evolved from 
a laborious and relatively insensitive assay into an extremely sensitive and highly flexible 
procedure, since the discovery of thermotolerant DNA polymerases and the development of 
automated thermal cyclers. 
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The basis of PCR fingerprinting is the amplification of polymorphic DNA through specific 
selection of primer annealing sites. Either constant primer sites bridge a single variable 
sequence domain or primers detect consensus sequences with variable distribution in the 
DNA. Differences in the distance between primer-binding sites or in the presence of these 
sites lead to synthesis of amplified DNA fragments which differ in length and can be detected 
by electrophoresis. Different PCR fingerprinting techniques such as amplification fragment 
length polymorphism (AFLP), random amplification of polymorphic DNA (RAPD) and multi 
locus sequence typing (MLST) have been developed. However, a major problem of these 
techniques is that these methods are often not equally discriminatory. 
In a letter to the editor in the Journal of Clinical Microbiology in 2003, several CF physicians 
and microbiologists therefore emphasized the need for harmonization of techniques and 
technique designations for genotyping clinical isolates of P. aeruginosa from CF patients 
(369). Epidemiological research, comparable to our studies, has been done in the UK, 
Canada and Australia (250, 251, 255). Most of these studies were based on Pulsed-Field Gel 
Electrophoresis (PFGE). 
Since our laboratory had already built up experience to genotype other species with RAPD 
and fAFLP, we have chosen to use these techniques (370, 371). This choice was supported 
by a publication of Speijer et al. (372), who showed that AFLP analysis was the most 
discriminatory method. D’Agata et al. (373) concluded that AFLP is comparable to PFGE for 
P. aeruginosa isolates. 
The culture and genotyping procedure used for P. aeruginosa isolates is described in article 
1  (see chapter III) (374). We assessed  the genotypic diversity of P. aeruginosa colonies, 
initially by RAPD-analysis, and further with fAFLP-analysis for representative strains of the 
different RAPD-types observed for each patient. In all cases studied here, isolates with 
identical RAPD-fingerprints also had identical fAFLP-fingerprints, ensuring that no unrelated 
isolates were grouped into the same RAPD-genotype. For each patient, all of the RAPD-
products were always obtained during the same thermal cycling and electrophoresis run, to 
avoid differences due to the limited inter-run reproducibility of the technique. fAFLP is 
generally known to be more reproducible and - due to automated digitisation of the 
fingerprints – it enables large-scale comparison of hundreds of fingerprints, which is 
impossible with RAPD-analysis. This combined approach of a rapid and cheap initial 
screening technique (RAPD-analysis) and a more sophisticated, more reproducible and 
digitized, but also more expensive and laborious technique (fAFLP-analysis), enabled us to 
genotype a large number of isolates in an affordable, reasonably convenient and a highly 
reliable and discriminatory manner. Moreover, the established library of fAFLP-fingerprints of 
CF P. aeruginosa strains can be used for further comparisons and long-term studies. 
 
 
Early detection of P. aeruginosa in CF patients 
 
Early detection of P. aeruginosa in CF patients is of utmost importance because aggressive 
antimicrobial therapy at first P. aeruginosa detection can prevent or postpone chronic    
P. aeruginosa colonization and the subsequent disease progression (see chapter II) . The 
standard method for assessing respiratory infection with P. aeruginosa is selective culture of 
sputum, oropharyngeal (OP) swabs or nasopharyngeal (NP) aspirates. Culture of broncho-
alveolar lavage fluid (BALF) is considered the gold standard for detection of P. aeruginosa, 
because it reflects colonization of the lower respiratory tract, but since BAL is an invasive 
procedure it is not often performed. It has been demonstrated that  sputum culture shows 
good correlation with BALF culture (375). First P. aeruginosa episodes however occur in 
young children who are not able to produce sputum. In this age group, diagnosis of P. 
aeruginosa infection is mainly based on culture of oropharyngeal swabs or nasopharyngeal 
aspirates. These techniques nevertheless have shown to be inferior in detection of P. 
aeruginosa. Therefore, there is an increasing interest in newer non-culture based  techniques 
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for early detection of P. aeruginosa. These techniques include serologic testing and 
molecular methods (PCR).   
This section  elaborates on  the value of the different diagnostic methods for early detection 
of P. aeruginosa in young children with CF.  
 
Diagnostic value of OP cultures for the detection of lower airway P. aeruginosa 
The diagnostic accuracy of  OP culture has important clinical implications, because it is the 
only non invasive way of assessing respiratory tract specimens in non sputum producing 
patients. OP cultures are taken by vigorously swabbing the posterior pharyngeal wall and 
tonsils. Several studies extend on the diagnostic value of OP cultures for detection of lower 
airway P. aeruginosa infection. They all come to similar conclusions.  
Ramsey et al. (376) collected simultaneous bronchial and OP specimens in 26 non-
expectorating CF patients and demonstrated that OP cultures have relatively good specificity 
(>90%), but  a poor sensitivity (46%) for detection of lower airway P. aeruginosa. The 
positive predictive value of OP cultures for detection of P. aeruginosa was 83%, whereas the 
negative predictive value of OP culture was 70%.  
Armstrong et al. (377) investigated 75 infants at a mean age of 17 months (range, 1-52 m) 
with CF diagnosed by neonatal screening by collecting 150 simultaneous BALF and OP 
specimens for quantitative bacterial culture. The sensitivity of throat swabs for detection of  
P. aeruginosa was 71%, the specificity was 93%, the PPV 57% and the NPV 96%. In 8 out of 
the 9 patients with P. aeruginosa isolated simultaneously from BALF and OP cultures,  
P. aeruginosa of OP and BALF were identical, as proved by  genotyping, indicating a high 
concordance of upper and lower respiratory cultures.  
Rosenfeld and colleagues (378) compared OP cultures with simultaneous BALF cultures 
(286 bronchoscopies) in 141 CF children younger than 5 years. In the youngest age group  
(< 18 months), OP cultures had a sensitivity, specificity, PPV and NPV for detection of  
P. aeruginosa of respectively 44%, 95%, 44% and 95%. In those older than 18 months 
sensitivity and PPV rose with sensitivity, specificity, PPV and NPV being respectively  68%, 
94%, 76% and 91%. The sensitivity of OP cultures improved as the lower airway bacterial 
density, cultured from simultaneous BALF samples, increased: sensitivity of OP culture was 
82% when > 105 cfu/ml P. aeruginosa were present in BALF.  
Burns et al. (49) performed 108 BAL procedures in 40 CF patients younger than 3 years. 
Bronchoscopy with BAL was performed annually, OP cultures were taken every three 
months. The PPV and NPV of OP cultures were 69% en 85%. Diagnostic accuracy could be 
increased by combining the results of two OP cultures, i.e. the OP culture concurrent with 
and the one preceding  the BALF culture. The PPV of this combination of OP cultures was 
93% and the NPV was 97%. Concurrent OP and BALF cultures both yielded P. aeruginosa in 
18  visits of 14 patients, each time genotypes OP and BALF isolates were identical. This 
confirms again the high concordance of upper and lower airway cultures.  
Conclusion: In young children, P. aeruginosa positive OP-cultures do not reliably predict the 
presence of P. aeruginosa in the lower airways. However, a negative OP-culture indicates 
that P. aeruginosa is unlikely to be present in the lower respiratory tract. In older children 
(with a higher prevalence of P. aeruginosa), positive predictive value is better than in 
younger children.  
 
Diagnostic value of nasopharyngeal aspirates for the detection of lower airway P. aeruginosa  
Although this is an established technique in many CF centres, the value of nasopharyngeal 
aspirates (NPA) in detection of lower airway pathogens has hardly been studied in CF 
patients. Taylor et al. (379) compared cultures of throat swabs and of NPA specimens in 47 
non expectorating CF children aged 6 months to 10 years. No significant differences were 
found in the rate of positive cultures for P. aeruginosa, S. aureus and H. influenzae. 
Concordance between the two sampling methods reached 98% for P. aeruginosa.  
Conclusion: Although culture of nasopharyngeal aspirate samples is a frequently used 
procedure, only one small study exists on the value of nasopharyngeal aspirates in de 
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detection of lower airway pathogens in CF. Relying on these scarce data, there is good 
concordance between throat swabs and nasopharyngeal aspirates for the detection of P. 
aeruginosa.  
 
Diagnostic value of serological methods in the early dectection of lower airway P. 
aeruginosa.  
Plenty of data exist on P. aeruginosa serology. The main antibody tests used in these studies 
are enzyme linked immunosorbent assay (ELISA) against whole cell protein or against single 
purified proteins (phospholipase C, exotoxin A, alkaline protease or elastase) and counter 
immuno electrophoresis (CIE) precipitating antibodies. Antibody levels determined by whole 
cell protein ELISA and levels of precipitins correlate well with each other and have a high 
sensitivity for chronic infection with P. aeruginosa (380). ELISA with single purified proteins 
has lower sensitivity for the diagnosis of  chronic infection (381). 
Detection of antibodies to P. aeruginosa has been investigated in different settings: 
Detection of antibodies against P. aeruginosa has initially been used to determine chronic 
infection with P. aeruginosa in CF patients and to monitor the response to antibiotic 
treatment in CF patients chronically infected with P. aeruginosa: patients with chronic 
infection generally have a firm antibody response and  CF patients chronically infected with 
P. aeruginosa who are treated intensively with antibiotics have a lower antibody response 
(112, 382-384).   
Longitudinal follow-up of P. aeruginosa antibody titres in children diagnosed with CF at 
young age shows higher numbers of children with positive P. aeruginosa serology than with 
P. aeruginosa positive respiratory cultures: Burns et al. (49) followed a cohort of 40 CF 
patients during the first 3 years of life. They were all diagnosed at young age (mean age at 
diagnosis 3.9 months), entered the study at a mean age of 11 months and underwent 
bronchoscopy with BAL at diagnosis and annually from then onwards. OP cultures and  
P. aeruginosa serology were carried out every 3 months. By the age of 3 years, 29 patients 
(72.5%) had shown positive cultures for P. aeruginosa (either from BAL, OP or both), 
whereas all but one patient (97.5%) had positive serum P. aeruginosa antibodies. All 18 
patients in whom P. aeruginosa was detected in BALF and 10 out of the 11 patients for 
whom P. aeruginosa was cultured only from OP samples demonstrated antipseudomonal 
antibodies. Ten out of 11 patients who did not have positive P. aeruginosa cultures had 
detectable antipseudomonal antibodies. The authors concluded that by the age of 3 years, 
only one patient lacked any evidence of P. aeruginosa contact, based on results of culture 
and serology. Unfortunately, no follow-up data of these patients are available.  
Longitudinal follow-up of P. aeruginosa antibodies in children diagnosed by newborn 
screening and followed from birth up to the age of 16 years shows that there are abrupt 
elevations in antibody titers with transition from no P. aeruginosa to nonmucoid  
P. aeruginosa and second elevations with transition from nonmucoid P. aeruginosa to 
mucoid P. aeruginosa (311).  
P. aeruginosa antibody titers correlate with the P. aeruginosa colonization status; as 
demonstrated by Pressler et al. (385) and Proesmans et al.(322). In these  studies, the  
P. aeruginosa antibody levels were significantly different between the different groups of  
P. aeruginosa colonization according to the Leeds criteria (chronic, intermittent, free of  
P. aeruginosa).  
Serology can help to predict the clearance of P. aeruginosa after eradication therapy: Ratjen 
et al. (386) assessed P. aeruginosa antibody titers before and after inhaled antibiotic therapy 
(tobramycine 80 mg bid for 12 months) in a cohort of 56 patients with a first ever  
P. aeruginosa isolation. P. aeruginosa antibodies decreased significantly in patients clearing 
the P. aeruginosa infection, whereas the titers increased in patients in whom antibiotic 
therapy failed to eradicate the organism. Kappler et al. (387) calculated the value of P. 
aeruginosa antibodies in the prediction of evolution to chronic infection in 27 CF patients 
intermittently infected with P. aeruginosa and in 68 CF patients free of P. aeruginosa. The 
authors calculated that if the serum antibodies were positive, it was very likely (PPV = 83%) 
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that the patient remained infected with P. aeruginosa after eradication therapy. If the serum 
P. aeruginosa antibodies were negative, the chance of elimination after eradication therapy 
was 58% (NPV).  
More recently, the interest in antibody tests for early detection of P. aeruginosa has 
increased. The studies are difficult to compare because of different patient groups studied 
(patients diagnosed by newborn screening versus mixed groups of CF patients with mixed  
P. aeruginosa colonization status), the use of different  serological methods, different cut-off 
values and different study designs (e.g. different frequency of respiratory cultures and 
serology samples). Moreover, most studies on the value of P. aeruginosa serology in early 
detection of P. aeruginosa in the young age group compare serology with OP cultures, with 
known limitations in diagnostic value of early detection (see above). The different study 
groups come to conflicting conclusions: while some authors strongly advocate the use of  
P. aeruginosa serology for early detection of P. aeruginosa (50, 388, 389),  others oppose 
this point of view (343, 386, 390) . 
The first to investigate the value of  serology as an early predictor of impending  
P. aeruginosa infection were Brett and colleagues (389). They studied 33 CF patients, from 
whom P. aeruginosa was isolated for the first time, during a period of 3 years. The titer of  
P. aeruginosa antibodies was elevated either at the first isolation of P. aeruginosa or up to 24 
months before this event in respectively 19 and 5 patients. Another 5 patients had titers that 
were within the control range before isolation of P. aeruginosa but that increased above the 
control range within 2 months following the first isolation of P. aeruginosa. In these 29 
patients continuing intermittent isolations of P. aeruginosa were accompanied by further 
increases in P. aeruginosa antibody titers. In the remaining 4 patients isolations of  
P. aeruginosa were not accompanied by an increase in specific antibodies.  
West et al. (50) followed  52 CF patients by OP or sputum cultures and P. aeruginosa 
serology at 6 months intervals for up to 180 months (15 years). Titers to cell lysate and 
exotoxin A were detected a mean time of 11.9 and 5.6 months before the first isolation of P. 
aeruginosa. In contrast, a titer to elastase was detected a mean of 41.1 months after the first 
isolation of the organism. The rise of anti–cell lysate and anti–exotoxin A titers occurred prior 
to, or coincided with, the first isolation of P. aeruginosa in 63% and 54% of the patients, 
respectively. On the contrary, not all patients with positive respiratory cultures developed 
positive P. aeruginosa serology.  
Milagres et al. (388)  followed 51 CF patients for two years: blood samples were obtained at  
an average interval of 6 months and respiratory secretions (OP culture or sputum) were 
cultured quarterly. In the group of 11 patients free of P. aeruginosa in the 2 years preceding 
and the first 17 months of the study, 9 (82%) had a positive P. aeruginosa serology in the 
first serum sample and all patients had positive serology at the end of the study. These 11 
patients showed negative P. aeruginosa respiratory cultures until the time of the 3rd blood 
sample . Eight (72.7%) individuals had their first P. aeruginosa isolation by the time of the 4th 
blood sample was collected. The time elapsed between the first positive serology and the 
first isolation of P. aeruginosa varied between 18 and 25 months (mean of 21 months). Three 
patients were still free of P. aeruginosa at the end of the study. In the group of 5 CF patients 
with intermittent P. aeruginosa isolation (not specified whether this was  before and/or during 
the study), 1 patient had a positive respiratory culture before P. aeruginosa antibodies were 
elevated, the 4 remaining patients demonstrated positive P. aeruginosa serology 3 to 12 
months before the isolation of P. aeruginosa from respiratory cultures.  
In a prospective 3 year study of Tramper-Stranders et al. (390) in 57 CF patients (age 4-14 
years), with 23% chronically colonized, 23% intermittently colonized and 54% free of P. 
aeruginosa according to the Leeds criteria,  P. aeruginosa serology was followed yearly, and 
cultures of respiratory secretions (sputum or OP swabs) at least once a year. A mean 
number of 6 respiratory cultures was taken during the 3 year study. In 5 of the 13 patients 
with a positive P. aeruginosa culture during the study period, positive P. aeruginosa serology 
preceded positive P. aeruginosa cultures and one patient had a simultaneous conversion to 
positivity for both culture and serology. Ten patients showed a transient positive serology 
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without any positive culture following. Weaknesses of this study are the low frequency of 
serology (once a year) and of culture (mean number of 6 cultures over 3 years) and the 
heterogeneous group of CF patients that was followed prospectively (only half of them not 
colonized by P. aeruginosa, without specification whether these were free of P. aeruginosa 
or never had any P. aeruginosa). Although these results are largely comparable with the 
West data (50) i.e. 46% in this study versus 54 to 63% of patients in the West study with 
positive serology preceding or concomittant with positive culture results, authors come to 
different conclusions on the usefulness of serology in early detection of P. aeruginosa in CF 
patients.   
Ratjen et al. (386) reported that 18 of 43  patients (42%) had positive antibody titers to  
P. aeruginosa at the time of the first P. aeruginosa infection. Fifty of the 198 patients (25%) 
who never had a positive culture for P. aeruginosa during the study period had positive  
P. aeruginosa  antibodies at one time point during the study. It is difficult to come to a 
conclusion based on these observation, as few information is given on study design 
(frequency of respiratory cultures, serum samples, follow-up time) of  these patient groups.  
Douglas et al. (343) recently provided interesting data on the value of P. aeruginosa antibody 
tests to predict lower airway infection with P. aeruginosa in two populations of young CF 
children. One population consisted of 76 predominantly asymptomatic infants and preschool 
children undergoing annual BAL procedure and serum sampling for P. aeruginosa serology, 
yielding 186 concurrent BAL and serum samples. The second group were 55 children 
undergoing BAL, OP and serum sampling during infective exacerbations; 162 paired 
samples were obtained in this group. In the first patient group, depending on which 
serological test used, serology had a sensitivity, specificity, PPV and NPV for detection of 
lower airway P. aeruginosa of 90-95%; 57-62%; 20-23% and 98-99% respectively. For the 
second patient group sensitivity, specificity, PPV and NPV were 46-84%; 52-82%; 34-43% 
abd 84-92% respectively. The diagnostic value of serology was in neither patient cohort 
sufficiently reliable to diagnose P aeruginosa infection with any certainty.  
The high NPVs observed suggest that serology may have clinical value in excluding lower 
airway infection with P aeruginosa in young children. However, in a population with a higher 
prevalence of P aeruginosa infection, the NPV of serology using either assay is likely to be 
too low to reliably exclude the presence of lower airway infection.  
To summarize, the results of these studies on the value of P. aeruginosa serology in the 
early detection of P. aeruginosa  indicate that positive serology can precede the isolation of 
P. aeruginosa by various time periods, but that this phenomenon is not observed in all 
patients. Some patients even have positive P. aeruginosa serology without subsequent 
positive P. aeruginosa respiratory cultures, although follow-up time might not have been long 
enough. It can also be discussed whether these cases represent false positive P. aeruginosa 
serology results or whether the P. aeruginosa infection has cleared spontaneously in these 
patients. When serology is available, it seems reasonable to follow serology together with 
conventional culture of respiratory secretions at regular intervals (monthly? quarterly?) and to 
be vigilant when antibody titers are rising.  
 
Conclusion: Current data indicate that  serological methods alone are not helpful in early 
diagnosis of P. aeruginosa infection but can be an adjunct tool, when followed longitudinally 
and in combination with regular culture of respiratory secretions.  
 
Diagnostic value PCR-techniques in the  early dectection of P. aeruginosa 
Over the last 15 years, several PCR formats targeting different genes for the detection of  
P.  aeruginosa have been developed (355, 357-365, 391, 392). These molecular techniques 
for detection of P. aeruginosa are yet not widely used in clinical practice. 
Studies show sensitivities between 93 and 100%, depending on the primers used (358, 362, 
391, 393). Some groups demonstrated a higher sensitivity of PCR compared to culture 
and/or serological tests for the detection of P. aeruginosa in respiratory samples of CF 
patients (391, 394, 395) while others found no difference (361, 366) or demonstrated a lower 
61 
 
sensitivity for PCR (363). Theoretically, PCR can be useful to detect the P. aeruginosa 
phenotypic variants that are not easily detected with conventional culture methods, whereas 
culture however will still be needed for susceptibility testing.   
Till 2010, the value of PCR in early detection of P. aeruginosa was only addressed in one 
study: Xu et al. compared PCR and conventional culture methods in a long term study for 
early detection of P. aeruginosa in 57 adult CF patients (391). Sputum was cultured for P. 
aeruginosa and in addition genomic bacterial DNA was extracted from the same sample and 
was amplified employing two species specific targets, i.e. the outer membrane protein gene 
locus and the exotoxin A gene locus. In 39 patients (22 P. aeruginosa positive and 17  
P. aeruginosa negative), a complete agreement between molecular and conventional 
detection techniques existed. In 10 patients a PCR positive/culture negative result was 
recorded and for 5 of these patients the sputum culture became positive over a mean period 
of 4.5 months (range 4-17 months).  
Conclusion: The value of PCR techniques in early detection of P. aeruginosa is addressed 
in only one study. In this study by Xu et al., the authors concluded that PCR technique was 
more sensitive than conventional culture methods for early detection of P. aeruginosa.  
 
General conclusion on the different techniques for early detection  of P. aeruginosa. : 
Early detection of P. aeruginosa in CF patients is of utmost importance, as early initiated 
therapy increases the chances of eradication, postponing the evolution to chronic infection 
with P. aeruginosa. Culture of BAL fluid is considered the gold standard for diagnosis of 
lower airway infection by P. aeruginosa, but is too invasive for regular use. OP cultures have 
a low sensitivity and serology has both a low sensitivity and specificity for detection of lower 
airway P. aeruginosa.  It is clear that more sensitive diagnostic techniques are needed. PCR 
based detection of P. aeruginosa on respiratory samples seems promising but more studies 
are needed.  
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CHAPTER III: Articles  
 
Introduction to the studies: rationale of this thesis  
Cystic fibrosis has always been a special field of interest in the Pediatric Pulmonology 
Department of the Ghent University Hospital. Since the establishment of CF centres in 
Belgium in 1999, CF care has become better organized. Paramedical co-workers, such as 
CF nurses, physiotherapists, dieticians, psychologists and social workers, joined the medical 
staff, optimizing CF care in many ways. Moreover, CF centre care facilitates the set-up of 
both inter-centre and multi-centre studies.  
As discussed in chapter II, P. aeruginosa  is one of the most common and clinically important 
pathogens in CF patients. By the age of 30 years, nearly 80% of the patients are 
intermittently or chronically colonized by P. aeruginosa, which adversely affects lung function 
and survival.  
Although knowledge on epidemiology of P. aeruginosa in CF patients, effect on disease 
progression, transmissibility, diagnosis and treatment has increased considerably over the 
last decades, several questions remain unanswered.  
In order to elucidate some of the many remaining unanswered issues in the field of  
P. aeruginosa in CF, we set up several studies, of which some are the topic of this thesis.  
1. The origin of P. aeruginosa in CF patients remains unclear for most patients. Patient-to-
patient transmission has been described and mainly results from prolonged and close 
contact. We previously demonstrated that the risk of a persistent patient-to-patient 
transmission of P. aeruginosa is low in a CF rehabilitation centre (396) and that no highly 
transmissible strains of P. aeruginosa circulate in the population of chronically colonized 
patients in Belgium (260). Consequently, the mode of acquisition of P. aeruginosa remains 
unclear for most patients. As P. aeruginosa is widely present in the natural environment, the 
possibility of acquisition from the environment has been raised. Can the organism be 
transferred from the home environment to the patient? This subject is investigated in the first 
study of this thesis “Pseudomonas  aeruginosa in the home environment of newly infected 
cystic fibrosis patients “ (374) 
 
2. After the first ever isolation of P. aeruginosa, patients may go through different episodes of 
colonization, preceding chronic colonization by months to years, eventually resulting in 
chronic infection. Several studies have demonstrated that treatment for early P. aeruginosa 
colonization episodes results in eradication in the majority of the patients and delays the 
evolution to chronic colonization. However, little is known on risk factors for chronic 
colonization and whether this therapy really eradicates P. aeruginosa or just temporarily 
suppresses the organism, with P. aeruginosa remaining in amounts too low to be detected by 
the current microbiological techniques. To solve these questions, we analyzed our data on 
genotypes of P. aeruginosa of first and subsequent colonization episodes. These are 
presented in “Genotype based evaluation of Pseudomonas  aeruginosa eradication 
treatment success in cystic fibrosis patients” (397).  
 
3. The best opportunity for successful eradication of P. aeruginosa in patients with CF is at 
the time of initial infection with nonmucoid, antibiotic-sensitive strains. In order to maximize 
the chance of successful elimination of P. aeruginosa, it is important to use sensitive 
techniques to detect any colonization of the airways as soon as possible. Currently, routine 
detection and identification of P. aeruginosa in respiratory samples is done by conventional 
methods such as culture on selective culture media and by recognition of biochemical 
characteristics.  Therefore, we were interested whether PCR based detection techniques can 
advance the diagnosis of P. aeruginosa colonization, allowing earlier initiation of  
P. aeruginosa eradication regimen and this resulted in a third study: “Comparison of culture 
and qPCR for the detection of Pseudomonas aeruginosa in not chronically colonized cystic 
fibrosis patients “ (365).  
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Chapter IV: Conclusions: 
 
In this thesis we studied different unknown aspects of acquisition, diagnosis and persistence 
of Pseudomonas aeruginosa in the respiratory secretions of CF patients in an attempt to 
answer the following questions:  
 
Can the home environment be a possible source of P. aeruginosa acquisition in CF 
patients? 
 
The origin of P. aeruginosa colonization in CF patients is currently unknown for most 
patients. Patient-to-patient transmission has been described and generally results from 
prolonged and close contact (260). As P. aeruginosa is widely present in the natural 
environment, the possibility of acquisition from the environment has been raised. The 
observation that CF patients can be protected from acquiring mucoid P. aeruginosa but not 
from acquiring nonmucoid P. aeruginosa through patient segregation (268) adds to this 
suspicion. Can the home environment of CF patients be a source of transmission? This topic 
was investigated in the first study: “Pseudomonas aeruginosa in the home environment of 
newly infected cystic fibrosis patients” (374). Here, we examined the degree of contamination 
with P. aeruginosa in the houses of CF patients and the possible environment-to-patient 
transmission by comparing environmental P. aeruginosa isolates with the patient isolates of 
50 CF patients with a first ever P. aeruginosa colonization episode. To our knowledge, a 
similar study has not been carried out before. We demonstrated that P. aeruginosa is not 
widely present in the homes of CF patients. P. aeruginosa was detected in only 6%  of the 
samples, originating from 36% of the houses. The data are comparable to data found in non-
CF houses in previous studies (277, 280, 281). A lower environmental contamination with  
P. aeruginosa was observed though, compared with the former studies in CF houses (277-
279). The different findings might be explained by the following differences in procedures:  
1) different sampling sites; 2) different sampling methodology; 3) different cleaning 
procedures carried out in the houses; and 4) the different P. aeruginosa colonisation status 
of the CF patients investigated. As P. aeruginosa is known to multiply overnight in the sinks, 
taking samples in the morning before use of taps and drains in the morning might have 
increased the positive P. aeruginosa cultures in our study.                                                                      
In nine patients (18%), the genotype of the environmental P. aeruginosa isolate was identical 
to that of the patient’s isolate, suggesting possible environment-to-patient transmission. It 
remains debatable however, whether the environmental isolates are the source of infection 
or conversely, whether contamination of the environment was caused by the patient. The 
only way to answer that question is by setting up a longitudinal study, taking regular cultures 
in the homes of CF patients before the first ever P. aeruginosa infection. This kind of setup is 
difficult, as it is possible that one has to sample years before the first ever infection is 
documented.                                                                                                                              
In our study, 72% of the environmental P. aeruginosa isolates were detected in the drains of 
the bathroom. This confirms the results of previous studies on the prevalence of  
P. aeruginosa in both CF and non CF houses indicating that drains are important reservoirs 
of P. aeruginosa. Therefore, bathroom drains should be targeted in the preventive cleaning 
procedures.  
These results indicate that the home environment is not the major source of P. aeruginosa 
infection in CF patients and as a consequence, the exact source seems to remain unknown. 
Based on this study and on literature data however, we can conclude that probably no major 
source of acquisition of P. aeruginosa for CF patients exists. Some patients acquire it from 
the environment, while others contract P. aeruginosa  through patient contact. The latter can 
be avoided by patient segregation but as P. aeruginosa is ubiquitously present in nature, 
acquisition in most patients seems unavoidable. Trying to keep away from all possible 
sources puts a  high psychological and social burden on the patients. Therefore, too strict 
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and poorly validated hygienic guidelines should be avoided. Further investigations should 
focus on determining factors facilitating acquisition of P aeruginosa in CF patients. 
 
 
What is the natural evolution after eradication therapy for a first ever colonization 
episode with P. aeruginosa in CF patients? Does treatment really eradicate the 
pathogen or does it only result in a temporary suppression of the organism? Can the 
evolution to chronic colonization be predicted? 
 
Several studies have demonstrated that treatment for early P. aeruginosa colonization 
episodes results in eradication in the majority of the patients and delays the evolution to 
chronic colonization. However, little is known on risk factors for chronic colonization and 
whether this therapy really eradicates P. aeruginosa or just temporary suppresses the 
organism, with P. aeruginosa remaining in amounts too low to be detected by the current 
microbiological techniques. In the second study of this thesis, entitled “Genotype based 
evaluation of Pseudomonas aeruginosa eradication treatment success in cystic fibrosis 
patients” (397), we  followed 41 CF patients prospectively after eradication treatment 
(consisting of oral ciprofloxacin and inhaled tobramycin or colomycin for three months) for a 
first ever P. aeruginosa colonization episode and evaluated the efficacy of eradication 
treatment by calculating the P. aeruginosa free time period after treatment and by comparing 
genotypes of initial and subsequent P. aeruginosa strains. Eradication treatment was 
successful in 34 (83%) of them, with over half (18 patients) experiencing a new  
P. aeruginosa episode after a median P. aeruginosa free time period of 7.5 months. In 
accordance with the data from the “15 year Danish experience with eradication treatment for 
P. aeruginosa“ study by Hansen et al. (336), reporting a significantly shorter P. aeruginosa 
free period between the first ever and second positive culture in CF patients becoming 
chronically “infected”, our study confirmed that patients becoming chronically “colonized” 
have a significantly shorter P. aeruginosa free interval between the first ever and second 
isolation event (i.e. median 0 months in the 11 patients becoming chronically colonized 
during the study period compared to 7.5 months in the 14 patients not becoming chronically 
colonized). As a result of these findings, we changed microbiological follow-up procedures at 
our CF center and now take cultures on a monthly basis after a first successful eradication 
treatment, decreasing the detection period to subsequent P. aeruginosa positivity, c.q. 
advancing new eradication treatments and probably postponing the onset of chronic 
colonization.                                                                                                                              
By incorporating genotyping of the P. aeruginosa isolates in the evaluation of eradication 
treatment, we were able to demonstrate that not only a short P. aeruginosa free time interval 
but also the detection of an identical P. aeruginosa genotype in the second isolate was an 
ominous sign for impending chronic colonization. In our study, a surprisingly high number of 
second P. aeruginosa isolates identical to the first ever isolate (i.e. 68%) was seen, whereas 
the two other and smaller studies revealed identical genotypes of P. aeruginosa isolates 
compared to the first ever isolate in 5 out of the19 patients (26%) (346) and 27% of 50 
episodes in 16 patients (337). Our results point rather to treatment failure, with merely 
suppressing but not really eradicating P. aeruginosa after an eradication treatment. The 
period with P. aeruginosa free samples might be explained to a certain extent by a lack of 
sensitivity of the routine microbiological detection methods used. The recurrence of isolates 
with the  same genotype could also be explained by reinfection fom the same environmental 
source. However, in our first study on the contamination with P. aeruginosa in the houses of 
CF patients with a first ever P. aeruginosa episode, we found that the home  environment of 
these patients is not heavily contaminated, making reinfection rather an unlikely explanation. 
The results of this study clearly indicate that there is a high need of more sensitive 
microbiological diagnostic techniques for the early detection of P. aeruginosa in CF patients 
not chronically colonized by this pathogen.        
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Can the diagnosis of impending infection with P. aeruginosa in CF patients not 
chronically infected by this pathogen be advanced by the use of PCR based detection 
techniques instead of or in addition to conventional microbiological culture 
techniques?  
 
This topic was addressed in the third study “ Comparison of culture and qPCR for the 
detection of Pseudomonas aeruginosa in not chronically infected cystic fibrosis patients” 
(365). In this study, we evaluated whether detection of P. aeruginosa by means of 
quantitative PCR (qPCR) techniques can advance the diagnosis of P. aeruginosa infection. 
Advancing the diagnosis gives the possibility to start eradication treatment earlier, probably 
increasing the likelihood of successful eradication and thereby postponing or even avoiding 
chronic colonization by P. aeruginosa. In order to investigate this, we prospectively followed 
397 CF patients, not chronically colonized by P. aeruginosa and examined respiratory 
secretions of these patients at least four times a year by means of both conventional culture 
and qPCR methods. Our results indicate that there is a good concordance between the 
results of conventional culture and qPCR for detection of P. aeruginosa in the vast majority of 
the samples (i.e. 816/852; 96%). Twenty-six samples, originating from 26 patients were 
culture negative but PCR positive. In these patients, early P. aeruginosa infection could be 
suspected but the follow-up samples became culture positive in only five of them, in four 
patients after 3 months (i.e. the next culture), in the remaining patient after 9 months, with 
two negative PCR/culture results in between. In the remaining 21 patients, the positive PCR 
signal became negative again and did not predict a positive culture at the next follow-up 
sample. We concluded that PCR positivity may have had a predictive value for impending 
infection in only a limited number of patients.  
These data, gathered on clinical samples, confirm the results of our previous laboratory study 
in which culture methods were equally sensitive to the combination of the most sensitive 
DNA extraction method and the most sensitive amplification assay, i.e. probe based qPCR 
(366). Our results do not confirm the results of two other reports (391, 398) on  the value of 
qPCR in early detection of P. aeruginosa. In the first study,  Xu et al. (391) compared blood 
agar, MacConkey agar and Pseudomonas isolation agar with PCR for detection of P. 
aeruginosa from sputa of 59 CF patients. In this analysis, five of the 10 patients with culture 
negative/PCR positive results converted to culture positivity after a time range of 4 to 17 
months (median 4.5 months). These authors concluded that PCR detected P. aeruginosa on 
average 4.5 months prior to culture. However, this should be interpreted with caution 
because of the low number of patients.                                                                                         
The second study, a large longitudinal analysis with a similar set up as ours was published in 
2010: Logan et al. (398) investigated 2099 sputa and throat swabs received from 183 
pediatric CF patients over a 29-month period in order to evaluate the efficacy of real-time 
PCR for the early detection of P. aeruginosa. Interestingly, in this analysis, the use of PCR 
was of more value than in our study for early detection of P. aeruginosa in CF patients not 
chronically colonized by this pathogen. In 26 out of the 80 specimens (32.5%) identified as 
PCR positive/culture negative for P. aeruginosa, the subsequent patient sample was P. 
aeruginosa culture and PCR positive, suggesting that PCR has the potential to advance the 
diagnosis of impending infection with P. aeruginosa. However, the authors do not mention 
the time lapse between the samples. Although the results of PCR in this report are 
promising, the authors are cautious in their conclusions. “Whether it is reasonable or 
acceptable to advise therapeutic intervention based on a PCR result in particular without the 
aid of antibiotic susceptibility data is unknown. However, early PCR detection has the 
potential to heighten the levels of awareness regarding potentially impending infection, 
thereby facilitating increased patient screening potential to detect P. aeruginosa earlier than 
the microbiologic culture.”                                                                                                           
It is not clear what makes the difference between the results of these two reports and our 
study. We followed these patients for a median time of 6 months (1-15 months).  Extending 
85 
 
the follow-up- time and including more samples will not alter the results; as it can be 
discussed whether a positive PCR result more than 6 months before a positive sputum 
culture for P. aeruginosa with negative results of PCR and culture in between really reflects 
early detection. In order to evaluate the value of PCR in early detection of P. aeruginosa,  
it might be more interesting to increase the frequency of PCR and sputum cultures after a 
first PCR positive/culture negative result .  
Differences can not be explained by inferior quality of the PCR technique used, as this has 
been analyzed comprehensively in a previous study (366). Yet, the different approaches of 
the studies and the availability of many different DNA-extraction protocols and PCR-formats 
make it often difficult to compare the different results and to come to unambiguous 
conclusions.  
.  
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Chapter V: Future perspectives    
We studied different unknown aspects of acquisition, diagnosis and persistence of 
Pseudomonas aeruginosa in the respiratory secretions of CF patients and demonstrated that 
the home environment is not the major source of P. aeruginosa infection in CF patients, that 
patients becoming chronically colonized have a significantly shorter P. aeruginosa free 
interval between the first ever and second isolation event, that the detection of an identical P. 
aeruginosa genotype in the second isolate is an ominous sign for impending chronic 
colonization and that a positive P. aeruginosa PCR may have had a predictive value for 
impending infection in only a limited number of patients.  
Although our research tried to answer some specific problems in daily CF care, it raises 
several new questions, emphasizing the urgent need for continued research. 
 
The source of P. aeruginosa acquisition remains unidentified for most patients. Some 
patients acquire it from the environment, while others contract P. aeruginosa  through patient 
contact. The latter can be avoided by patient segregation but as P. aeruginosa is ubiquitously 
present in nature, acquisition in most patients seems unavoidable. Trying to keep away from 
all possible sources puts a  high psychological and social burden on the patients, as clearly 
demonstrated in the results of questionnaires published by Steinkamp (275) and Ullrich et al. 
(276). Therefore, too strict and poorly validated hygienic guidelines should be avoided.  
 
Further investigations should focus on determining factors facilitating acquisition of P 
aeruginosa in CF patients. Currently, we are studying the role of modifying genes in the 
clinical course of CF related lung disease. We examined 82 Single Nucleotide 
Polymorphisms (SNPs) in 22 genes contributing to the innate immunity and 385 SNPs in 110 
genes contributing to the inflammation of the lung in 200 CF patients (Haerynck et al.,in 
preparation). Once facilitating polymorphisms for early P. aeruginosa acquisition or fastened 
respiratory deterioration in CF patients can be recognized, a more strict follow-up schedule 
should be considered for this group of CF patients.   
 
As successful eradication mainly depends on early treatment, research should focus  on  
early detection of P. aeruginosa. Relying on our research and on current literature data, 
neither PCR nor P. aeruginosa serology alone can predict impending infection but any 
positive test can heighten the awareness. The ideal combination of tests should be 
determined. 
 
Evaluation of a successful eradication treatment should not only be based on culture results 
and determination of the P. aeruginosa free time period and the delay of chronic colonization 
but also on the comparison of the genotypes of successive P. aeruginosa isolates after 
eradication therapy. We are investigating the reliability of a genotype based definition of 
chronic colonization through analysis of  long-term follow-up data  of CF patients after a first 
ever P. aeruginosa colonization episode. Ideally, this genotype based definition should 
anticipate the diagnosis of chronic colonization compared to the currently widely used 
European consensus or Leeds definition of chronic colonization and unequivocally determine 
in which patients new eradication therapies for P. aeruginosa are not worthwhile starting any 
more.  
 
A batch of possible antimicrobial therapeutic compounds for CF people is under investigation 
presently. Setting up patient trials is time-consuming and challenging though and the prior 
efficacy evaluation of the different potential future therapies should be optimized in order to 
analyze which components are valuable investigating in patient trials. In most of the currently 
used models only single genotypes of P. aeruginosa are studied, whereas in the patients’ 
airways sometimes two or three genotypes of P. aeruginosa and moreover numerous other 
species are present. In addition, the current biofilm models lack the patient mucus, the 
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patient leukocytes and the different medications the patient is receiving. Briefly, only an ex 
vivo sputum model can mimic as closely as possible the lung environment of the individual 
patient and consequently, this model might enable personalized medicine. At present, our 
research group is developing an ex vivo sputum model in order to study the therapeutic 
effect of antimicrobial drugs in CF patients with a respiratory exacerbation.   
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Chapter VI: Summary  
Cystic fibrosis (CF) is a life-shortening genetic multi-organ disease, affecting more than     
100 000 people worldwide and about 1000 people in Belgium. The disease is caused by a 
defect in the CFTR protein, resulting in a defective transport of chloride across the cellular 
membrane. CF affects all racial and ethnic groups, but it is more common among 
Caucasians. Life expectancy of CF patients has increased considerably over the last 
decades, due to advances in treatment and better organised patient care. While in the fifties, 
most CF patients did not survive infancy, over the years the mean survival has steadily 
increased to a mean predicted survival age of  37.4 years in the US (12).  
 
P. aeruginosa is one of the most common and clinically important pathogens in CF patients . 
By the age of 30 years, nearly 80% of the patients are intermittently or chronically colonized 
by P. aeruginosa,  which adversely affects lung function and survival. P. aeruginosa strains 
causing early colonization or infection usually have a nonmucoid phenotype and are 
relatively antibiotic-sensitive. Aggressive treatment of these early colonizing strains often 
successfully eradicates P. aeruginosa. Early treatment of initial P. aeruginosa colonization 
can therefore postpone the onset of chronic colonization and maintain or increase pulmonary 
function. Chronic mucoid P. aeruginosa colonization is usually impossible to eradicate, and 
the goal of antibiotic treatment is then to suppress, rather than to eliminate the pathogen.  
In this thesis, we studied different unknown aspects of acquisition, results of eradication 
therapy and early diagnosis of P. aeruginosa in CF patients.  
 
The origin of P.  aeruginosa in CF patients is unclear for most patients. Patient-to-patient 
transmission has been described and mainly results from prolonged and close contact. As  
P. aeruginosa is widely present in the natural environment, the possibility of acquisition from 
the environment has been raised. The different studies on the prevalence of  P. aeruginosa 
in CF health care settings demonstrate that particularly sinks are heavily contaminated.  
Genotypes of environmental P. aeruginosa sometimes matched patient strains and in one 
patient CF health-care environment-to-patient transmission was strongly suspected. In 
contrast to the extensive studies on patient-to-patient transmission and on the presence of P. 
aeruginosa in the hospital environment, there are only a few reports on the prevalence of P. 
aeruginosa in the home environment of both CF and non-CF patients. None of them studied 
the possibility of environment-to-patient transmission, neither did they compare genotypes of 
P. aeruginosa isolates recovered from either patients or from their home environment. We 
investigated the possibility of CF home environment-to-patient transmission in the first study 
of this thesis:  “Pseudomonas  aeruginosa in the home environment of newly infected cystic 
fibrosis patients”.  We demonstrated that P. aeruginosa is not widely present in the homes of 
CF patients: P. aeruginosa was detected in only 6% of the samples, originating from 36% of 
the houses. In nine patients (18%), the genotype of the environmental P. aeruginosa isolate 
was identical to that of the patient’s isolate, suggesting possible environment-to-patient 
transmission. It remains debatable however, whether the environmental isolates are the 
source of infection or conversely, whether contamination of the environment was caused by 
the patient. In our study, 72% of the environmental P. aeruginosa isolates were detected in 
the drains of the bathroom. Therefore, bathroom drains should be targeted in the preventive 
cleaning procedures. These results indicate that the home environment is not a major source 
of P. aeruginosa infection in CF patients and as a consequence, the exact source still seems 
to remain unknown at first sight. Based on this study and on literature data however, we can 
conclude that probably no major source of acquisition of P. aeruginosa for CF patients exists. 
Some patients acquire it from the environment, while others contract P. aeruginosa  through 
patient contact. The latter can be avoided by patient segregation but as P. aeruginosa is 
ubiquitously present in nature, acquisition in most patients seems unavoidable. Trying to 
keep away from all possible sources puts a  high psychological and social burden on the 
patients. Therefore, too strict and poorly validated hygienic guidelines should be avoided. 
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Further investigations should focus on determining factors facilitating acquisition of P 
aeruginosa in CF patients. 
After the first ever isolation of P.  aeruginosa, patients may go through different episodes of 
colonization, preceding chronic colonization by months to years, eventually resulting in 
chronic infection. Early treatment for P. aeruginosa colonization/infection episodes is now 
considered the standard of care in the CF centres. Although the effect of eradication 
treatment regimens on the deferral of chronic colonization CF patients has been reported, 
longitudinal data on the genotype of P.  aeruginosa isolates after initial colonization and 
eradication treatment; i.e. the efficacy of the eradication therapy are limited. We analyzed our 
data in “Genotype based evaluation of Pseudomonas  aeruginosa eradication treatment 
success in cystic fibrosis patients” and demonstrated that patients becoming chronically 
colonized have a significantly shorter P. aeruginosa free interval between the first ever and 
second isolation event and that the detection of an identical P. aeruginosa genotype in the 
second isolate is an ominous sign for impending chronic colonization. In our study, a 
surprisingly high number of second P. aeruginosa isolates identical to the first ever isolate 
(i.e. 68%) was seen, whereas the two other and smaller studies revealed identical genotypes 
of P. aeruginosa isolates compared to the first ever isolate in just about 25% of the episodes. 
Our results indicate treatment failure, with merely suppressing but not really eradicating P. 
aeruginosa after an eradication therapy. More studies are needed to determine the optimal 
treatment regimen and duration of eradication treatment.  
 
Early detection of P. aeruginosa in CF patients is of utmost importance, as early initiated 
therapy increases the chances of eradication, postponing the evolution to chronic infection 
with P. aeruginosa. Culture of BAL fluid is considered the gold standard for diagnosis of 
lower airway infection by P. aeruginosa, but is too invasive for regular use. OP cultures have 
a low sensitivity for detection of lower airway P. aeruginosa. The results of the studies on the 
value of P. aeruginosa serology in the early detection of P. aeruginosa  indicate that positive 
serology can precede the isolation of P. aeruginosa by various time periods, but that this 
phenomenon is not observed in all patients. It is clear that more sensitive diagnostic 
techniques for early detection of P. aeruginosa in CF patients not chronically colonized by 
this pathogen are needed. Therefore, we were interested whether PCR based detection 
techniques can advance the diagnosis of P. aeruginosa colonization, allowing earlier 
initiation of P. aeruginosa eradication regimen and this resulted in a third study: “Comparison 
of culture and qPCR for the detection of P. aeruginosa in not chronically colonized cystic 
fibrosis patients. Our results indicate that there is a good concordance between the results of 
conventional culture and qPCR for detection of P. aeruginosa in the vast majority of the 
samples but that PCR positivity may have a predictive value for impending infection in only a 
limited number of patients. These results do not confirm the results of the two other reports 
on the value of PCR for early detection of P. aeruginosa, with respectively in 50% and 32.5% 
of the samples identified as PCR positive/culture negative for P. aeruginosa, a subsequent 
patient sample positive for P. aeruginosa culture and PCR, suggesting that PCR has the 
potential to advance the diagnosis of impending infection with P. aeruginosa. Relying on our 
research and on current literature data, neither PCR nor P. aeruginosa serology alone can 
predict impending infection but any positive test can heighten the awareness. The ideal 
combination of diagnostic tests for early detection of P. aeruginosa in not chronically 
colonized CF patients is still to be determined. 
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